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ABSTRACT: In our effort to find small molecule treatments of advanced prostate cancers (PCs), 
the novel series of indolyl and indolinyl propanamides (series II and III) were discovered as 
selective androgen receptor degraders (SARDs).  Initial studies of androgen receptor (AR) 
antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity 
but poor metabolic stability.  Cyclization to II and III produced sub-micromolar AR antagonism 
and protein degradation selective to AR and AR splice variant (AR SV).  II and III maintained 
potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells, and were efficacious in 
Enz-R xenografts, suggesting their potential to treat advanced PCs.  Disclosed is the design, 
synthesis, and biological activity of novel SARDs that could potentially be used for the treatment 
of a wide spectrum of PCs including castration resistant, Enz-R, and/or AR SV dependent 
advanced PCs that are often untreatable with known hormone therapies.  
KEYWORDS: Structure-activity relationship, Selective androgen receptor degrader, Androgen 
receptor, Androgen receptor splice variant, AR-V7, AR escape mutants, Antagonist, Prostate 
cancer, Antiandrogen resistance, Enzalutamide resistance, Castration-resistant prostate cancer, 
N-terminal domain, Ligand binding domain, Prostate-specific antigen, AR activation function 
domain-1.  
 
1. INTRODUCTION 
The androgen receptor (AR) has been the focus of prostate cancer (PC) therapies since 
Huggins and Hodges’s discovery in the early 1940s that androgens promote PC growth.1-3 PC is 
one of the most common malignancies diagnosed in men. According to the American Cancer 
Society in 2017, 161,000 men were diagnosed with PC in the United States with 26,730 deaths 
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estimated from the disease.4  More than 3 million men in the United States are currently living 
with PC.5 The AR plays an important role not only for the development and function of the 
normal prostate gland, but also for the growth and maintenance of PC cells.6-7 Androgen 
deprivation therapy (ADT), via suppression of endogenous synthesis (e.g., goserelin or 
abiraterone) and/or AR blockade (e.g., bicalutamide (4), enzalutamide (5), and apalutamide (6) 
in Figure 1), is the standard of care for metastatic PC. Re-activation of the AR-axis despite 
treatment can occur even despite castration levels of testosterone or 5-dihydrotestosterone 
(DHT), suggesting the need for new mechanisms for AR antagonism.8-10 
An AR antagonist 5 improved survival of men with metastatic castration-resistant prostate 
cancer (CRPC).11 Earlier this year, the AR antagonist 6 was approved for use in non-metastatic 
CRPC based on its ability to extend the metastasis-free survival as compared to placebo.12-13 
Unfortunately, primary and acquired resistance to 5 (and other antiandrogens) is common,14-15 
e.g., the mutations AR F876L or F876L-T877A switch 5, at higher levels, from AR antagonist to 
agonist making PCs enzalutamide-resistant (Enz-R).14 Further, cross-resistance between 5 and 6 
based of F876L16 and cross-resistance in general between abiraterone and/or ligand binding 
domain (LBD)–directed antiandrogens is well known.17-19  Moreover, AR splice variants (e.g., 
AR-V7 and D567es) lacking the LBD have been reported as pan-resistant CRPCs.19 The 
development of resistance to antiandrogens is a growing concern and new strategies to block AR 
function in CRPC are required.17-19  
Our first generation of selective androgen receptor degraders (SARDs) were metabolically 
labile secondary and tertiary amines (I) lacking in vivo activity when administered orally that 
were designed by structural modification of the AR antagonist 1 [2-hydroxy-4-(4-
isothiocyanatophenyl)-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)butanamide] and the 
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tissue-selective AR agonist enobosarm (2, (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-
cyanophenoxy)-2-hydroxy-2-methylpropanamide) (Figure 2).  Class I was exemplified by UT-69 
(3, (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((6-cyano-[1,1'-biphenyl]-3-yl)(methyl)amino)-
2-hydroxy-2-methylpropanamide) whose tertiary amine was cyclized to form indoles (II) and 
indolines (III), which are characterized herein as potent AR antagonists and SARDs with a broad 
activity profile in models of prostate cancer, and in vivo AR antagonism when orally 
administered.  E.g., SARDs of II and III exhibited strong AR antagonistic activity in vitro in 
transcriptional activation and cellular proliferative assays, including in models of enzalutamide-
sensitive and Enz-R PCs, and CRPCs.  Additionally, II and III showed selective AR degradation 
of full-length (FL; e.g., from LNCaP cells (T877A)) and splice variant (SV; e.g., from 22RV1 
cells (AR-V7)) isoforms of AR, all at sub to low micromolar treatment levels, and in a variety of 
PC cell contexts, including Enz-R PCs (e.g., MR49F cells).   
The ability to degrade SV AR in this study suggested the potential of II and III to treat 
various currently untreatable advanced and refractory PCs.  E.g., those lacking the ligand binding 
domain (LBD) of AR such as AR-V7 and D567es AR truncations, which are not susceptible to 
ADT, abiraterone, or LBD-directed antiandrogens (e.g., 4-6 (Figure 1)), and are associated with 
short survival.20-21  Further, in vivo investigations found that analogs within the II and III series 
overcome a variety of escape mutants including F876L and F876L/T877A that are known to 
emerge due to treatment with 5.  These mutations convert 5 and 6 to agonists, conferring 
resistance to prostate cancer cells and tumors22 via an agonist switch as seen with other LBD-
binding antiandrogens, e.g. W741L for 4 and T877A for flutamide (N-(4-nitro-3-
(trifluoromethyl)phenyl)isobutyramide).23-24   
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The intractability of truncation mutants and the frequency of the agonist switch mutations 
suggest that novel ways, potentially LBD-independent ways, of targeting the AR are needed.  
The initial design, synthesis and biological evaluation of these SARDs as putative treatments of 
Enz-R and other advanced PCs is discussed.  Moreover, these SARDs are dual acting agents, i.e., 
potent inhibitors and degraders of AR, providing a higher evolutionary barrier to the 
development of resistance to II and III. For all these reasons, we believe that SARDs may 
provide a next generation of AR antagonists to treat a variety of refractory and/or advanced PCs, 
including Enz-R and AR-V7 dependent PCs.  
Herein we rationalize our profile of screening assays designed to overcome Enz-R PC 
including our initial SARD structure activity relationship (SAR).  Further, II-III were evaluated 
in in vitro anti-proliferation and in vivo xenograft models of Enz-R PC.  In overview, we report 
three series of SARDs (I-III) possessing a novel mechanism of action in SV AR and escape 
mutant models of Enz-R PC in vitro and in vivo assays. Despite a variety of competing 
preclinical approaches to address Enz-R, there has been little success in the clinic, leaving this 
and other refractory prostate cancers as unmet clinical needs.  It is our belief that the SARDs 
such as reported herein may resurrect the AR axis as a target for overcoming Enz-R, AR-V7 
dependent, and/or refractory CRPCs.   
  
2. RESULTS  
Design.  Since even before our discovery of diaryl nonsteroidal androgens in 1998,25-27 
we have designed and developed many variations of AR agonist and AR antagonist 
propanamides with a recent focus on selective androgen receptor degraders (SARDs or AR 
degraders; where selectivity refers to degrading only the AR protein) such as 3 and 7 (Figures 1 
and 2).28  SAR studies of the propanamides demonstrated that the linkage to the B-ring plays a 
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key role in determining the agonistic vs. antagonistic activities (Figure 2), which can be fine-
tuned via B-ring substitution.25-27, 29-40 Many ethers (and thioethers in vitro) are agonists whereas 
most other linkages are partial to full antagonist.  E.g., enobosarm (ostarine, MK-2866, GTx-024, 
S-22, 2 in Figure 1) showed strong in vivo36, 40-42 tissue-selective androgen receptor modulation 
(SARM) activity.  In other words anabolic tissue-selectivity is revealed by increased lean body 
mass reflective of muscle mass changes, increased bone mineral density and performance 
enhancement in humans across at least 22 clinical trials.43,44  
We also have reported high affinity p-NCS B-ring substituted propanamides with a 
variety of linkages to the B-ring such as methylene (e.g., 1 which is a butanamide), secondary 
and tertiary amine, ether, thioether, and sulfone propanamides.27 Though compounds like 1 were 
designed as antagonists that irreversibly bind the AR via the NCS moiety, we were only able to 
demonstrate moderate (M) anti-proliferation in prostate cancer cell lines (IC50 values of 20.6-
23.8 M in various PC cell lines).  Seeking to improve the efficacy in models of PC, we explored 
the B-ring substitution in a series of secondary and tertiary amines (i.e., class I SARDs).  The 
high inhibitory potency of the amines led to the discovery of 3 (Figure 2) and its characterization 
as our initial SARD providing an entry into AR degradation and helping to define the structural 
characteristics of propanamide SARDs.28  Fusion of the tertiary amine of 3 into the B-ring 
retained both the AR inhibition and SARD activities at very high potency but with improved 
ligand efficiency and in vitro stability, as exemplified by the indole 7 in Figure 1.28 Further, 3 
and 7 did not degrade glucocorticoid receptor (GR), estrogen receptor (ER), or progesterone 
receptor (PR) expressed in cells, demonstrating the AR selectivity of I-III.28  The ability to 
degrade AR was generalizable to a series of N-linked indoles (II), indolines (III) (Figure 2), and 
various other bicyclic heterocylces (not reported here).   
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Our initial [or seminal] SARD SAR exploration is detailed herein.  Further, class II-III 
SARDs in Figure 2 are evaluated for in vitro anti-proliferation and anti-xenograft activities in 
models of Enz-R PC.  Unlike previous antiandrogens lacking SARD activity such as 4 and 5, I-
III have the potential to overcome all AR-dependent PC models tested to date, including Enz-R 
and/or SV AR expressing CRPCs.  
Initial Biological Evaluation of Class I.  Herein, we have sought to design new 
molecules to potently inhibit and degrade AR with the specific aim to treat CRPC. Initially, we 
tested a couple of high affinity but weakly antiproliferative butanamides (i.e., methylene-linked 
propanamides) such as 1 and 8 for AR antagonistic activity and their ability to degrade AR at the 
protein level as shown in Table 1.  SARD activity reported as percent degradation captures the 
AR protein levels relative to vehicle treated and are reported qualitatively using the following 
abbreviations: -, no degradation (inactive); +, < 30% degradation (weak SARD activity); ++, 31 
~ 60% degradation (moderate SARD activity); +++, 61 ~ 90% degradation (strong SARD 
activity); ++++: > 90% degradation (complete SARD activity). [The terms inactive, weak, 
moderate, strong and complete AR degradation and the symbols are used interchangeably.]  High 
affinity 1 (0.032 M)27 did not inhibit AR transactivation in vitro (> 10 M) despite weak (SV) 
to moderate (FL) SARD activity; whereas non-binder 8 showed sub-micro molar level in vitro 
inhibition (0.392 M) and moderate FL SARD activity. 
Though interesting, these activity profiles did not provide potent inhibition and FL AR 
and SV AR degradation in a single molecule, nor consistent antagonism.  However, changing the 
methylene linkage to amine provided a series of compounds with the in vitro profile we were 
looking for, the ability to potently inhibit and degrade FL and SV AR (Table 1).  Biaryl B-ring 3 
emerged as the lead molecule from series I, demonstrating highly potent inhibition in vitro (48 
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nM) and strong SARD activity that almost completely degrades FL and SV AR at sub-M and 
low M levels, respectively (Table 1).28 The shifted nitrogen atom illustrated in Figure 2 
produced a unique biological action with the potential to overcome CRPC whether based on AR 
point mutation or AR truncation. However, the biphenyl B-ring and methyl substituent of the 
amine proved to be metabolic liabilities, limiting the bioavailability of 3, making observation of 
AR antagonism in vivo inaccessible.28  These metabolic liabilities were removed by cyclization 
of 3 to form classes II (indole) and III (indoline) SARDs possessing a nitrogenous heterobicyclic 
B-ring (Figure 2) which did not require aryl substitution and provided new Lipinski-compliant45 
chemotypes (Table 2) to co-optimize for antagonism, SARD activity (infra), and drug 
metabolism and pharmacokinetic (DMPK) properties (infra), with emphasis on SARD efficacy. 
We synthesized the indolyl II and indolinyl III classes of new derivatives and evaluated 
the SAR of the SARD activities of these compounds.  The A-ring was conserved except for two 
variants at the 3’-position, namely 3’-CF3 and 3’-Cl anilides (Table 2).  In overview, II-III 
maintained the high efficacy degradation of FL AR at 1 M dose and SV AR at 10 M dose, and 
high potency antagonism (two digit nano-molar range) of 3.  Unlike the previous nonsteroidal 
AR agonists or antagonists including 4-6 and abiraterone, the structurally optimized members of 
II-III showed AR antagonism in in vivo models including models of CRPC.   
Synthesis.  Compounds 1 and 8 previously reported by our group27, are representative 
examples of a series of carbon-linked AR antagonists and were synthesized as previously 
reported.  2, an ether linked agonist, was also synthesized as previously reported for other ether 
linked propanamides.29, 46  1 and 2 each have a nitrogenous substituent on the aromatic B-rings.  
In 1 the nitrogen atom in the isothiocyanate group is to the B-ring whereas 2 has a  nitrogen 
atom in the cyanide group (Figure 2).  
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In our design, we shifted the nitrogen into the linkage to produce multiple series (I-III) 
with a common unique biological profile which is optimally represented as 3 and 7.  3 was 
synthesized as previously reported (see supplementary section).28  The present study illustrates a 
series of indolyl (II) and indolinyl (III) small molecule SARDs which were designed and 
synthesized as diaryl (S)-propanamides with two variations of the anilide ring, 3’-CF3 and 3’-Cl 
anilides.  SAR studies of II-III focused on substitution of the B-ring.  The synthesis of II and III 
is outlined in Scheme 1.  We prepared both the class II and III starting from a chiral hydroxyl 
bromide 11 (Scheme 1) reacted with an aniline (9 or 10) to form an R-bromoaniline (12 or 13), 
followed by oxirane (14 or 15) formation in the presence of K2CO3 (or other basic conditions), 
via a known procedure.27, 37, 47-48  In overview, compounds of II were prepared in very good yield 
by Method A via activation of substituted-1H-indoles (16) with sodium hydride and, its 
subsequent reaction with the oxiranes 14 or 15.  Similarly, compounds of III were prepared by 
Method B which uses LDA to activate substituted 1H-indolines (17) to react with the same 
oxiranes (14 or 15), as depicted in Scheme 1.  Indoline 21f was prepared by reduction of indole 
19f as described in the Experimental Section.  Although most compounds 16 and 17 were 
commercially available, indoles 16a-c were de novo synthesized in our lab as described in the 
Experimental Section.  
The R-bromoanilides 12 and 13 were synthesized as enantiomerically pure products via 
the conserved intermediate bromo-acid 11 (R-isomer) which was synthesized in large quantities 
from D-proline as the chiral auxiliary, as previously reported.27, 49 Final products were diaryl (S)-
propanamides.  To further probe the SAR, the opposite isomer of 7, namely 7r was prepared 
from the S-isomer of compound 11 derived from L-proline via the same synthetic method to yield 
an (R)-propanamide.  
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Overview of the Biological Evaluation of Class II and III SARDs.  SAR-guided 
substitution of the B-ring allowed co-optimization of AR antagonism and AR degradation 
activities for the treatment of Enz-R or SV AR expressing CPRC.  The screening regimen 
included determination of AR LBD binding affinity, inhibition of R1881-activity in vitro 
transcriptional activation (sometimes stated as in vitro antagonism herein), and degradation of 
FL and SV ARs, as shown in Tables 1, 3 and 4.  Once potent full antagonism and strong pan-
SARD activity were accomplished in a single molecule, DMPK criteria (e.g., see in vitro liver 
microsome stabilities studies reported infra) were also considered in the selection of SARDs to 
be tested for in vivo efficacy.  
In vitro screening: AR LBD binding (Ki), wild type antagonism (IC50), and FL and 
SV SARD activity (% degradation).  In separate batches of the stated in vitro assays, 7 (5-F 
indole)28 was included as a positive control, so that variations in the assays could be recognized.  
The desired screening profile consisted of:  (1) strong (+++) or complete (++++) efficacy FL AR 
degradation in LNCaP cells possessing T877A (recently reported as T878A with all other amino 
acid numbers also shifted by +1, whereas traditionally numbered as T877A) mutant AR 
conferring resistance to hydroxyflutamide,  (2) strong (+++) or complete (++++) efficacy SV AR 
degradation in 22RV1 cells possessing AR-V7 truncation mutant AR, which is theoretically 
resistant to all LBD-targeted antiandrogens, and  (3) at least mid nanomolar (nM) potency in 
vitro antagonism to block any residual wildtype or mutant AR that might be present despite 
strong to complete degradation.  (Binding affinity to purified LBD AR was determined but was 
not used to select leads, as discussed in the next section.)   
Following screening, promising compounds were tested in DMPK assays, e.g., the mouse 
liver microsome (MLM) assay reported infra, to determine their relative stability and/or to locate 
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their metabolic liabilities such that they can be blocked.  This allows us to advance only 
relatively stable compounds possessing all three screening criteria to in vivo testing, including in 
models of CPRC.   
LBD vs. Activation Function-1 (AF-1) Binding and Antagonism. Equilibrium-binding 
affinity (Ki) of series II and III was measured using binding to purified GST-tagged human AR 
LBD in competition with a non-metabolizable and stable steroidal androgen, [3H]-mibolerone 
([3H]MIB) (at 1 nM).  The specific binding at each concentration of the test compounds was 
obtained by subtracting the non-specific binding of [3H]MIB, and the values are expressed as the 
percentage of the specific binding in the absence of the compound of interest.   
All assay batches were normalized to the respective Ki value for DHT in each assay, 
which was considered as 1 nM. The concentration of compounds II or III that reduced the 
specific binding of a radiolabeled [3H]MIB by 50% (IC50) was determined by computer fitting 
the data to the following equation using SigmaPlot® and four parameter logistics.  
We hypothesized that series I-III will need to make at least a transient interaction with AR 
to enable its ubiquitination-dependent degradation,28 suggesting the importance of AR binding.  
However, when we tested the degradation properties of II and III, these values correlated poorly 
with the AR LBD affinity assay described herein (Tables 3 and 4). Better correlation was seen 
between the level of degradation in LNCaP and 22RV1 cells and AR antagonism.  Further, the 
series II and III exhibited antiproliferative activity in Enz-R cells (see MR49F50 data infra) 
suggestive of phenotypic effects resulting from the antagonism and SARD activities reported here.  
Though generalization is difficult, SARDs of series II and III produced hit or miss nM level 
binding (ranged from 0.047 to >10 M) and more consistently potent AR antagonism (ranged from 
0.026 M to 0.835 M).  Regarding selectivity of antagonism, equipotent PR antagonism was 
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observed for 728 and selected members of II and III (data not shown), but not other steroid 
hormone receptors.  E.g., indoles 19f and 19b and indolines 21a and 21b lack significant GR 
antagonism in in vitro transactivation studies, as shown in Supplementary Figure S1.  Further, 19f 
and 19b also lack the ability to antagonize the ER in vitro.  Given the lack of antagonism of GR 
or ER with the above and other SARDs, we do not routinely screen for GR and ER degradation.   
The poor correlation between AR LBD binding and antagonist or SARD activity is clearly 
seen for the optical isomers 7 and 7r.28 They demonstrated comparably high efficacy SARD 
activities despite their disparity in binding affinities (0.267 M (7) vs. >10 M (7r)).  We have 
previously addressed possible rationalizations of this behavior, which include the N-terminal 
domain (NTD) binding site for our SARDs reported for 7, 7r, and 3 which differentiates our 
compounds from other SARDs or proteolysis-targeting chimaeras (PROTACs).28   
Several lines of biophysical evidence substantiate that AF-1 binding is generalizable for I-
III, including fluorescence polarization for 19b (Supplemental Figure S2) and previously for 328 
and 728, and previous NMR studies for 728 and 7r28, as well as these and other biophysical methods 
applied to these and other structural classes of SARDs not reported here (unpublished results).  
The fluorescence polarization study with 19b demonstrated an interaction of the SARD with AF-
1 domain. The interaction was revealed as a shift in the fluorescence emitted by the tyrosine and 
tryptophan residues in the presence of 19b, which is consistent with the aforementioned previous 
results.  The AF-1 domain is present in the N-terminus of the AR and is common to all forms of 
the AR expressed in cells.  We believe AF-1 binding to be a general mechanism of action for our 
SARDs but do not routinely screen new compounds biophysically.   
13 
 
Moreover, our SARDs may induce degradation by perturbing AR folding or modulating 
the protein-protein interactions of AR.  These would not necessarily be reflected in AR LBD 
binding affinities.  
The previous notwithstanding, the AR LBD affinity (for most compounds) and in vitro 
antagonist properties of II and III ranged from comparable to favorable relative to the standard 
known AR antagonists currently employed clinically for the treatment of PC.  E.g., 4, 5, and 6 
had binding affinities of 0.509 M, 3.641 M, and 1.452 M, and in vitro antagonism of 0.248 
M, 0.216 M, and 0.016 M (the last value was previously reported51), respectively, compared 
to 7 binding of 0.267 M and antagonism of 0.085 M.  Despite the standard agents being potent 
antagonists, only 6 demonstrated any SARD activity albeit with lower efficacy (<30%), as 
shown in Table 3.  As expected and consistent with steroidal AR agonists, the nonsteroidal 
SARM 2 stimulated expression of FL and SV AR as seen by Western blot, affirming that AR 
protein levels in the SARD assay behaved as expected.  In contrast, the series II and III 
degraded FL AR at 1 M dose and also SV AR at 10 M (22RV1) with efficacies ranging from 
30-100%.  In some cases, the reduction of AR protein levels was nearly 100% and occurred at 
nM levels (infra).  Our current view is that the SARD activity of these compounds is of primary 
importance to their ability to overcome CRPC.  Consequently the SAR discussion below will 
focus on SARD activity.   
Our SARDs display a novel mechanism of action, which, by its nature, provides a 
rationale for an expanded disease scope of efficacy and a barrier to the development of 
mutational resistance.28  Below, AR antagonism will only be discussed as a secondary 
consideration in the biological evaluation. 
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SARD assays in LNCaP and 22RV1 cell lines.  We screened all compounds of II and III 
for their ability to degrade FL (LNCaP) and SV (22RV1) androgen receptors (Tables 1, 3 and 4).   
Western blots for representative compounds from II and III are shown in Figure 3.  SARD 
activity was measured by treating cells with several doses, e.g., 0.1, 1.0 a n d / or 10 M, of 
SARDs in the presence of agonist (0.1 nM R1881).  LNCaP or 22RV1 cells were plated in full 
serum containing medium. Medium was replaced with 1% charcoal-stripped fetal bovine serum 
(csFBS) containing medium and the cells were maintained in this medium for 2 days. Medium 
was changed again after 2 days and the cells were treated as indicated in the figures in the 
presence of 0.1 nM R1881. Cells were harvested 24 h after treatment and Western blot for AR 
and actin was performed using specific antibodies.  
The Western blots were quantified densitometrically and the AR/actin values are 
represented as fold change or percent change from vehicle-treated cells. Panel A in Figure 3 
showed the degradation of FL AR in LNCaP cells and Panel B showed degradation of SV AR in 
22RV1 cells, while actin in each lane serves as an internal standard to correct for variations in 
protein loading which complicate the visual interpretation of the immunoblots. The percent (%) 
degradation values reported in Tables 1, 3, and 4 are normalized for variations in protein loading 
and are relied upon for relative efficacy determinations.  Dose-dependent degradation was seen 
in LNCaP cells for 21f (3’-Cl, 5-F, 6-Ph indoline), 19f (3’-Cl, 5-F, 6-Ph indole), 19b (3’-Cl, 4-F 
indole), 20b (3’-CF3, 4-F indoline), 21b (3’-Cl, 5-F indoline) and 21d (3’-Cl, 6-F indoline).  
From Figure 3A, it is apparent that >50% of FL AR is already degraded at 1 M of these 
SARDs, i.e. nM range SARD activity.  SV AR degradation (the lower molecular weight band in 
Figure 3B; upper band is disregarded in % degradation values) for the selected SARDs 21f (3’-
Cl, 5-F, 6-Ph indoline), 19f (3’-Cl, 5-F, 6-Ph indole), 21a (3’-Cl, 4-F indoline), and 7 (3’-CF3, 5-
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F indole) was observed to be dose-dependent and generally about 10-fold less potent (Figure 3B) 
than FL AR degradation, which is consistent with our other SARDs.  Some compounds degrade 
FL AR better than SV AR (e.g., 21d) or vice versa (e.g., 18f) (Tables 3 and 4), whereas the 
optimal SARD will potently and completely (i.e., ++++) degrade both and has a high potency 
antagonism.  21f comes closest to displaying the perfect profile with complete/strong 
degradation of FL/SV and antagonism comparable to 5, 0.244 M (21f) vs. 0.216 M (5), but 
weaker than other SARDs reported here. 
Selectivity and mechanistic aspects of SARD activity:  The AR selectivity of degradation 
among steroidal receptors has been shown previously, e.g. 3 and 7 were shown to not degrade 
the expression of PR, ER, and GR28.  Supplemental Figure S3 further supports this view as it 
demonstrates that 19b and 19f do not degrade ER in MCF-7 cells.  Moreover, the absence of 
significant antagonism of GR by 19b, 19f, 21a and 21b nor ER antagonism by 19b and 19f 
(Figure S1 discussed supra) further supports the lack of degradation of these receptors.  
Although LBD binding may not correlate to degradation, steroidal receptor antagonism would be 
expected if that steroid receptor is degraded.   
To validate that SARDs function by reducing the stability of protein (as opposed to 
decreasing rate of protein synthesis, e.g., lowering mRNA levels, etc.), we conducted an 
experiment with 19f in the presence of the general protein synthesis inhibitor, cycloheximide 
(Supplemental Figure S4). Treatment of LNCaP cells with 50 µM cycloheximide or 10 µM 19f 
did not significantly reduce the protein levels at the evaluated time-points. However, when the 
cells were treated with the two molecules together, significant down-regulation of the AR was 
observed. These results suggest that the SARDs function by destabilizing the AR protein that has 
already been synthesized as opposing inhibiting protein synthesis.  This agrees well with an 
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earlier validation of 3 and 7 using very similar methodology.28  Further, 7 was previously 
characterized as increasing rate of AR degradation by targeting AR to the proteasome in LNCaP 
cells using bortezomib.28 That result was confirmed for indoles reported first herein using the 
same methodology but in an EnzR LNCaP cell line (see infra), suggesting that proteosomal 
degradation of AR can overcome EnzR.  
SARD SAR.  As described above, two classes of SARDs were prepared, II (indoles) and 
III (indolines), as either 3’-CF3 (18 and 20 series) or 3’-Cl (19 and 21 series) anilines as shown 
in Table 2.  The B-rings of II and III were substituted with a variety of electron withdrawing 
(e.g., halogens, nitro, trifluoromethyl, etc.) and/or phenyl groups.  FL and SV SARD analyses 
were routine screening of II and III, along with the binding and antagonism assays described 
above.  SARD activities were determined via Western blots employing NTD directed antibody to 
determine AR levels.  The FL AR and SV AR experiments were performed in LNCaP and 
22RV1 cells, respectively, treated at 1 M and 10 M, respectively.  We have found that, in 
general, FL AR is more sensitive than SV AR to degradation by II and III, however, the ability 
to degrade both is preferable for treating CRPC.  
We used Western blot to determine degradation of proteins.  As it is difficult to obtain 
IC50 values due to low throughput nature of the system, we quantified the AR bands and 
normalized to loading controls and provided as percent degradation.  The percent degradation 
values were segregated into five qualitative ranges of values:  1. no degradation is symbolized as 
(-) and termed as inactive; 2. < 30% degradation (weak SARD activity) is symbolized as (+); 3. 
31% to 60% degradation (moderate SARD activity) is symbolized as (++); 4. 61% to 90% 
degradation (strong SARD activity) is symbolized as (+++); or 5. > 90% degradation (complete 
AR degradation) symbolized as (++++).  [The terms inactive, weak, moderate, strong and 
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complete AR degradation and the symbols are used interchangeably.]  The SARD SAR 
discussion below describes the SARD data in Tables 3 and 4.  Based on the current data set, it is 
clear that SARD values for FL (LNCaP) and SV (22RV1) AR are not univocal, which may result 
in differential efficacy across different PC models.  Since the goal is to degrade both FL and SV, 
these data are discussed in aggregate as SARD activity (see below).   
3’-CF3 (18 series) vs. 3’-Cl (19 series) A-ring:  In general, it is unclear whether series 18 
(3’-CF3) or series 19 (3’-Cl) is superior.  E.g., comparison in Table 3 of 7 vs. 19c (both 5-F 
indoles) and comparison of 18b vs. 19b (both 4-F indoles) seem to slightly favor 3’-CF3.  
However, it is less clear in the case of 6-F substitution, 18c (-/+++ for FL/SV) vs. 19d (+++/- for 
FL/SV).  In general, the substitution with 3’-CF3 vs. 3’-Cl produced approximately equivocal 
SARD results.  
Indole (18 series and 19 series) vs. Indoline (20 series and 21 series):  In many cases 
only a small advantage is seen for indolines, e.g., 20a vs. 18a (both unsubstituted), 20e vs. 18c 
(both 6-F), and 21d vs. 19d (both 6-F).  However, comparing indoline 21f vs. indole 19f (both 5-
F, 6-Ph substituted) suggests that the double bond reduction contributes to 21f SARD activity.  
Further, both compounds that induced complete (++++) FL degradation were indolines, 21d and 
21f. 
Electron withdrawing groups (EWG) at positions 3-7 of B-ring:  In general, electron 
withdrawal on the B-ring seems to favor the SARD activities of II and III.  For indoles (II), 
compare 19a (3-F; +++/+++), 7 (5-F; +++/+++), 7r (R-isomer of 7; 5-F; +++/+++), or 18b-18f 
(monofluorination or mononitration at positions 4-6) to the unsubstituted 18a (+/++).  For 
indolines (III), compare 20b (4-F; +++/+) and 20e (6-F; +++/++) to the unsubstituted 20a 
(+++/++).  As outlined above, fluorination generally augmented for indoles or retained for 
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indolines SARD activity relative to the unsubstituted analog. Indoles seemed to benefit more 
from EWG substitution and fluorination at the 3- (19a) or 5- (7, 7r) position is generally optimal.  
Nitration of the indole ring, e.g., 18e (5-NO2) and 18f (6-NO2), showed strong SV SARD 
activity, and very potent in vitro antagonism with IC50 values of 0.103 M and 0.058 M, 
respectively, but weaker FL SARD activity.  Fluorination at the 4 (18b, 19b, 20b, 21a), 5 (19c, 
21b), or 6 (18c, 19d, 20e, 21d) positions of II or III produced SARD portfolios with lower % 
degradation values for FL or SV than 7 (5-F).  Larger 5-halogenations on the indole ring (II) 
abolished activity (18j (5-Br), 18k (5-I)), whereas on the indoline ring (III) it was better 
tolerated, e.g., see 21c (5-Br; ++/-) even though ~1 M antagonism was seen for all.  5,6-
Dihalogenation of 3’CF3 indolines (III) such as 20f (5,6-diF; ++/++) and 20g (5-Cl, 6-F; -/-; 
agonism) did not improve upon the SARD activity over the monohalo analog 20e (6-F; +++/++), 
and further did not conform to the desired screening profile due to partial agonism in vitro which 
represents a liability in the treatment of PC.  Contrary to this, 21e (5,6-diF in the context of 3’-
Cl; +++/++) had an improved SARD profile vs. 21b (5-F; ++/+) and 21d (6-F; ++++/+) and was 
a very potent and pure antagonist (0.032 M).  Although 21d (6-F indoline) produced complete 
FL AR degradation (and very potent antagonism (0.037 M)), the SV AR degradation was weak 
making it a less than ideal compound for CRPC.  [Moreover, insertion of a nitrogen atom into 
the B-ring of II (18n; 5-CN) produced only weak degradation (+/+) compared to 7 (5-F).]   
B-ring 3-position:  As suggested above, 3-F (on B-ring) seemed to contribute to SARD 
activity based on 19a vs. 18a, however, the 3’-position (A-ring) is also a variable in this 
comparison.  Also, 3-methylation was tolerated (18g vs. 7), but did not increase activity.  Larger 
substituents, polar and nonpolar, abolished SARD activity completely such as 18l (3-CO2H), 
18m (3-CO2Et), and 19g (3-Ph, 5-F), possibly suggesting limited steric tolerance.  However, 
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18m and 19g did retained moderate antagonism of 0.972 M and 1.032 M, respectively.  This 
position was not substituted for indolines III, but would explore novel structural space due to the 
tetrahedral carbon.  
Addition of phenyl to B-ring:  The phenylation of indoles (II) was not tolerated at 3, 4, 
and 5 positions.  E.g., see 19g (3-Ph, 5-F), 18o (4-Ph), and 18p (4-F, 5-Ph) in which activity was 
abolished.  This is consistent with steric intolerance at the 3 and 5 positions as discussed above. 
Steric tolerance at the 6-position of the indole ring is suggested by 18i (5-F, 6-Ph; ++/+) and 19f 
(5-F, 6-Ph; ++/++) where mostly moderate SARD activity was maintained upon addition of 6-Ph 
group, but lower than 7 (5-F; +++/+++).  In contrast, 18q (4-F, 6-(4-fluorophenyl)) was inactive 
despite weak antagonism (0.898 M) and strong binding (0.062 M).  Interestingly, 6-
phenylation on the indoline ring (III) improved SARD activity, i.e., 21f (5-F, 6-Ph indoline; 
++++/+++) was much improved over 21b (5-F indoline; ++/+) [or 19c (5-F indole; +++/+)].  
Unlike other indolines, 21f produced complete FL AR and strong SV AR degradation efficacy, 
and demonstrated potent antagonism (0.244 M).  The structure of 21f is reminiscent of the 
biphenyl B-ring of 3 of class I, and may suggest further exploration of the indoline 6-position.  7 
(5-F; +++/+++/ 0.085 M) and 19a (3-F +++/+++/ 0.045 M) also produced impressive CRPC 
in vitro screening portfolios. 
In vitro metabolic stability in mouse liver microsomes (MLM).  Several compounds of 
each class were selected to be further evaluated for in vitro metabolic stability in MLM with co-
factors for enzymes of both phase I and phase II metabolism.  This allows the calculation of half-
life (T1/2) and intrinsic clearance (CLint) values as a predictor of the DMPK of series II and III as 
shown in Table 5.   
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In overview, the CLint of II and III is rapid (T1/2 ranges from 9.13 min to 36.32 min), 
especially compared to 5 (10.04 h in humans; as previously reported)51 and 2 (360 min in MLM) 
43 which are orally active and dosed daily in humans.  The unsubstituted indole 18a has a T1/2 of 
13.66 min.  5-Fluorinated 7 has an equivocal half-life but improved SARD activity (Table 3) 
whereas 4-fluorination (18b; 36.32 min) increased the half-life of 18a by approximately 3-fold, 
but reduced SARD activity.  In general, 4-substituted indoles, and to a lesser extent, 3- or 5- 
substituted indoles have improved stability compared to unsubstituted 18a.  This may be due to 
the steric blocking, or stabilization, of metabolically labile aryl protons on the indole.  The most 
stable SARD reported is 18b (4-F indole; 36.32 min) is ~3-fold more stable than 18a 
(unsubstituted) or 7 (5-F), but this is still far from optimal metabolic stability.  Although SARD 
activity is preserved in some of these longer T1/2 compounds, the relative instability of II and III 
compared to the standard agents suggested that the pharmacokinetics of these SARDs may need 
to be vastly improved in order to reveal the in vivo pharmacodynamic profile of SARDs II and 
III.  Nonetheless, II and III were tested in in vitro (e.g., antagonism, SARD, and anti-
proliferative assays) and in vivo (e.g., xenografts) models of CPRC (e.g., F876L, MR49F, and 
22RV1) and demonstrated significant efficacies as will be discussed infra.  Efforts to improve 
the SARD efficacy and DMPK characteristics of II and III are ongoing. 
Models of refractory and CRPC   
Overview of refractory PC models employed:  LNCaP is a well characterized PC cell line 
which expresses a mutant full-length AR (T877A).  The T877A mutation confers resistance to 
hydroxyflutamide,52 but in the absence of other mutants, is sensitive to 5.  22RV1 cells express 
both FL AR (H874Y)53 and SV AR (AR-V7).  22RV1 cells demonstrate a more promiscuous 
ligand binding than wild-type AR (LBD AR) and respond to low levels of androgens and a wide 
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spectrum of other natural and synthetic steroid hormones, mechanisms proposed to contribute to 
tumor progression following androgen ablation53.  Further, the AR-V7 in 22RV1 supports 
constitutive AR activity and lacks a LBD such that ADT, abiraterone, and traditional 
antiandrogens including 5 and 6 cannot block growth of these cells.  Our SARD screening 
employs the combination of LNCaP and 22RV1 cells, respectively, to predict whether a 
particular SARD can degrade [wildtype] and various escape mutant FL (e.g., T877A, H874Y, 
W741L, etc.) and SV (e.g., AR-V7 and D567es, etc.) ARs, respectively, which emerge due to 
treatment with clinically approved antiandrogens.  As new agents are approved, new mutant FL 
and SV AR will be discovered as resistance conferring escape mutants.   
Recently, a basis for 5 and 6 resistance was discovered to be either the F876L point 
mutation or F876F/T877A double mutant.  Enz-R MR49F LNCaP cells harbor the double mutant 
and serve as a model of Enz-R CRPC, which can be tested, e.g., in in vitro assays of antagonism 
of transcriptional activation, SARD activity, or cell anti-proliferation, or as in vivo xenografts.  
Xenografts are particularly informative as they reveal the adequacy of the combination of the 
pharmacodynamic and DMPK profiles [in the animal species tested] for any given molecule and 
provide a proof of concept for whether a particular class of agents is ready to be translated 
toward human testing (e.g., IND-enabling studies such rat and dog toxicity, etc.).  We produced 
CRPC xenografts by growing implanted MR49F cells to 100-300 mm3 in intact animals (i.e., 
endogenous androgens are present), removing androgens via castration, and re-growing in the 
absence of androgen.  These castration and Enz-R PC xenografts better reflect the CPRC 
phenotype seen clinically where patients typically are treated with ADT and 5 or 6 and despite 
this, reactivation of the AR axis occurs.  Various members of II and III demonstrated activity in 
each of the models described above (see infra), including in vivo models, despite poor metabolic 
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stability (Table 5) in the same species, suggesting that metabolically stable SARDs with 
comparable or improved pharmacodynamic profiles would be promising candidates for treatment 
of many refractory PC’s, including Enz-R CPRC.   
In vitro models of CRPC:  Antagonism, SARD, and antiproliferation in Enz-R cell lines 
SARDs inhibit transcriptional activation of F876L.  To validate that II and III can 
antagonize the R1881-driven transcriptional activation of mutant AR F876L, we transfected COS 
cells with F876L AR with a glucocorticoid response element (GRE)-driven luciferase reporter 
construct, and a Renilla reporter construct as a control for transfection efficiency.  The GRE-
LUC construct consists of synthetic consensus response elements that are detected by AR, PR, 
GR, and mineralocorticoid receptor. This construct is widely used in the nuclear receptor field to 
determine the activity of these receptors. Cells were treated 24 h after transfection with 0.1 nM 
R1881 (AR agonist) and a dose response of SARDs II and III.  Luciferase (and Renilla) assays 
were performed 48 h after transfection and reported as relative light units (RLU).  COS is not a 
prostate cancer cell line, so transfection with F876L does not convert them to Enz-R PC.  Figure 
4A (top middle panel) demonstrated potent (low nM) but not full efficacy antagonism by 5 of 
R1881-driven F876L transactivation, whereas wt AR inhibition was less potent (low M) and 
full efficacy.  Importantly, at high concentrations (>1 M), 5 acts as an agonist of F876L 
transactivation (top right panel of Figure 4A), which is not seen in wt AR.  This is indicative that 
F876L acts like an agonist switch escape mutant of 5 therapy.   
Given that II and III were structurally novel high potency AR antagonists with a unique 
biological activity profile, representative compounds [i.e., 7 (5-F indole), 18b (4-F indole), 18c 
(6-F indole), 19c (5-F indole), 19b (4-F indole), and 20b (4-F indoline)] were tested for their 
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ability to overcome the agonist switch behavior. Approximately equipotent nM range, full 
efficacy antagonism of R1881-driven transcriptional activation was observed in both F876L and 
wt. This suggested that our SARDs would also exhibit activity in models of Enz-R (e.g., MR49F 
cells) and primary PC possessing wt AR.   
SARD activity and cellular anti-proliferation in a model of Enz-R PC (MR49F):  To 
ensure that SARD activity was also maintained in a Enz-R cell line, SARD assays were 
performed in MR49F LNCaP cells containing the F876L/T877A double mutant.  As seen in 
Figure 4B, 19f (5-F, 6-Ph indole) and 19b (4-F indole) degraded this mutant FL AR in MR49F 
cells in the low M and high nM range, respectively, consistent with the relative activities seen 
in Tables 3 and 4 Immunoblots suggest that 19b and/or 19f demonstrated comparable potency of 
SARD activity in the Enz-R LNCaP (Figure 4B) when compared to the parental 5 sensitive 
LNCaP shown supra (Figure 3A).  This conservation of SARD activity of these compounds 
suggests that their SARD activity is not highly sensitive to small changes in AR amino acid 
sequence or the transformed cellular context of the Enz-R cells.  5 was inactive in SARD activity 
assays in LNCaP (FL) and 22RV1 (SV) cells and was not expected to be a SARD in the MR49F 
context (or any cellular context), as demonstrated in the lower panel of Figure 4B.  The 
preservation of SARD activity even in the Enz-R context suggested that II and III may exhibit 
anti-proliferative and/or anti-tumor activities.   
Anti-proliferative assays in MR49F cells showed that 21a (4-F indoline), 19b (4-F 
indole), and 19f (5-F, 6-Ph indole) completely and dose-dependently inhibited cell growth with 
estimated IC50 values of less than 3 M for 21a and 19b, and less than 1 M for 19f (Figure 5A).  
For 19b at least, this correlates well with in vitro antagonism and SARD activity in MR49F cells 
(Figure 4), suggesting that II and III retained their unique biological profile in Enz-R PC.  By 
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comparison, 5 demonstrated weak and incomplete efficacy as revealed by poor dose-dependence 
and only partial inhibition of growth. E.g., growth inhibitions at 3 M, 10 M and 30 M were 
approximately 30%, 15%, and 45%.  This result demonstrated the Enz-R nature of these MR49F 
cells, and further affirmed our ability to overcome the Enz-R phenotype with representative 
examples of II and III, supporting testing in MR49F xenografts.  Further, the AR-dependence of 
the anti-proliferative action of our SARDs is demonstrated in Figure 5B by the lack of activity of 
19b and 19f in the AR-negative PC cell line PC-3 at doses as high as 10 M, removing the 
possibility of non-specific cytotoxicity underlying anti-proliferative and AR degradation 
activities.   
Reversal of SARD activity in MR49F cells by inhibition of the proteasome:  To 
provide a mechanistic basis for the AR degradation observed with II and III, we tested the 
effect of a proteasome inhibitor on AR degradation by 19f and 19b in the same model of Enz-R 
PC as the xenografts (Figure 6). This experiment builds upon the observed AR destabilization 
by 19f as shown in Figure S4, discussed supra.  MR49F cells were treated with 19f and 19b in 
the presence and absence of bortezomib.  Cycloheximide, an inhibitor of protein synthesis, was 
included in all treatments to prevent de novo AR synthesis.  AR/GAPDH ratios based on 
densitometric quantitation demonstrate that bortezomib treatment alone (lane 3; ratio of 1.6) 
increased AR levels compared to vehicle treatment (lane 1; ratio of 1).  In contrast, 19f and 19b 
produced comparable high efficacy AR degradation (lanes 2 and5; ratios of 0.3 and 0.3) that 
was completely reversed by equimolar bortezomib (lanes 4 and 6; ratios of 1.2 and 0.9) 
producing AR levels comparable to vehicle treatment.  This reversal of 19b- and 19f-dependent 
degradation by bortezomib supports the hypothesis that ubiquitination-dependent proteasomal 
degradation is enhanced by 19b and 19f.  The ubiqutin-proteasome system is a tightly 
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regulated, highly specific pathway responsible for the vast majority of protein turnover within 
the cell.  The ability to target the AR to the ubiquitin-proteasomal pathway even in this model 
of EnzR PC helps to rationalize the anti-tumor activity (discussed infra) observed despite poor 
PK properties.   
 
In vivo antagonism:  Hershberger assays and enzalutamide resistant LNCaP xenografts  
Hershberger assays.  Uncertain of whether our combination of pharmacodynamic (pan-
antagonism and pan-SARD activities) and pharmacokinetic (e.g., poor stability in MLM) 
properties would be sufficiently robust to observe AR antagonism in vivo, we performed 
Hershberger assays on several selected II and III orally administered in intact mice and rats.  
Surprisingly, despite poor MLM stabilities, the tested SARDs (21a, 21b, 18c, 19f, 7, 19b, 19c, 
19a and 21f) caused atrophy of AR-dependent seminal vesicles tissue in intact mice (Figure 7A, 
left panels) whereas vehicle did not have any effect (0% change).  Similar efficacy atrophy was 
also observed for 21a and 21b in rats (Figure 7A, right panel) and was demonstrated to be dose-
dependent in prostate and seminal vesicles, with up to ~40% change in organ weights relative to 
castrated control (100%).  Though only partial efficacy at 40 mg per kg, this confirms that 
orally administered compounds are being absorbed and distributed to the site of action in these 
organs and suggests that these compounds should also distribute to tumors in xenograft models 
to exert anti-tumor effects in sensitive models.   
MR49F Xenografts in mice:  Following the demonstration of in vitro activity in MR49F 
and in vivo antagonism in Hershberger assays, there was confidence in our ability to demonstrate 
activity in Enz-R xenografts.  MR49F xenograft experiments were completed with 19f and 19b.  
19b and 19f satisfied all the criteria for a next generation AR antagonist for EnzR PC that 
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includes stronger AR-LBD binding, lower AR antagonistic IC50, better degradation of AR and 
AR-SV degradation than enzalutamide.  19b was the best 3’-Cl indole (19 series) in vitro (Table 
3), however 19f produced superior in vivo antagonism in intact animals (Figure 7A), despite non-
optimal in vitro values.  Hence, we chose 19b and 19f for further characterization to see whether 
in vitro or in vivo data was more predictive of anti-cancer activity.  
MR49F xenografts were established by implanting these Enz-R LNCaP cells (a kind gift 
from Dr. Martin Gleeve, University of British Columbia) mixed with Matrigel (BD Biosciences, 
San Jose, CA) at 1:1 ratio and injecting subcutaneously in NOD SCID gamma (NSG) mice.  
Once tumor sizes reached 100-200 mm3, the mice were castrated and the tumors were allowed to 
regrow as CRPC.  The animals were randomized once the tumors started to regrow and treated 
with vehicle (polyethylene glycol-300:DMSO  85:15 ratio) or 100 mg per kg of SARDs 19f or 
19b for 14 d.  In Figure 7B, 19f and 19b significantly reduced the tumor volume with a 40-60% 
tumor growth inhibition (TGI), whereas 5 did not significantly reduce the growth of MR49F 
xenografts.  Though almost equivocal, 19f appeared to perform slightly better than 19b in this 
proof-of-concept experiment, possibly suggesting in vivo data was a better predictor of anti-
cancer activity.     
Further, the significant levels of TGI activity indicated that the oral bioavailability 
demonstrated in Hershberger assays translated to adequate levels of 19f and 19b in tumor to 
reveal [at least to some extent] the pharmacodynamic behavior of our SARDs.  Though complete 
tumor regression was not accomplished as may be possible with improved pharmacokinetic 
properties, the proof-of-concept that our SARDs can overcome Enz-R CRPC in vivo was 
established through the susceptibility of these Enz-R xenografts to 19f and 19b.  This promising 
result is surprising given the poor metabolic stability of II and III as a whole in the same species 
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(mice) as seen in MLM (Table 5; T1/2 for 19f and 19b were 9.13 min and 11.77 min).  These 
experiments provide hope that our SARDs with their unique biological profile could be used to 
overcome 5 and by extension 6 and abiraterone resistances in CRPC patients.    
 
3. CONCLUSIONS AND DISCUSSION 
In our effort to find bioactive small molecules for the treatment of advanced prostate 
cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III, 
respectively) were discovered to be selective androgen receptor degraders (SARDs).  The first 
generation of SARDs were metabolically labile secondary and tertiary amines (I) lacking in vivo 
activity that were designed by structural modification of the androgen receptor (AR) antagonist 1 
[2-hydroxy-4-(4-isothiocyanatophenyl)-2-methyl-N-(4-nitro-3-
(trifluoromethyl)phenyl)butanamide] and tissue-selective AR agonist enobosarm (2, (S)-N-(4-
cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide).  Class 
I was exemplified by 3 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((6-cyano-[1,1'-biphenyl]-
3-yl)(methyl)amino)-2-hydroxy-2-methylpropanamide] whose tertiary amine was cyclized to 
form indoles (II) and indolines (III).  II and III are characterized herein as potent AR 
antagonists and SARDs with a broad activity profile in models of PC, and in vivo AR 
antagonism when orally administered.  E.g., SARDs of II and III exhibited strong AR 
antagonistic activity in vitro in transcriptional activation and cellular proliferative assays 
including in models of 5 sensitive and resistant PCs, and castration resistant PCs (CRPCs).   
Additionally, II and III showed selective AR [protein] degradation of FL (e.g., from 
LNCaP cells (T877A)) and SV (e.g., from 22RV1 cells (AR-V7)) isoforms of AR, all at sub to 
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low micromolar treatment levels, and in a variety of prostate cancer cell contexts including Enz-
R PCs (e.g., MR49F).  The ability to degrade SV AR in this study suggested the potential of II 
and III to treat various currently untreatable advanced and refractory PCs.  E.g., those lacking 
the LBD of AR such as AR-V7 and D567es AR truncations, which are not susceptible to ADT, 
abiraterone, or LBD-directed antiandrogens (e.g., 4-6), and are associated with short survival.21, 
54 Further, in vivo investigations found that analogs within the II and III series overcome a 
variety of escape mutants including F876L and F876L/T877A (MR49F) that are known to 
emerge due to enzalutamide (5) treatment.  These mutations convert 5 and 6 to agonists, 
conferring resistance to PC cells and tumors22 via an agonist switch mechanism as seen with 
other LBD-binding antiandrogens, e.g. W741L for 4 and T877A for flutamide (N-(4-nitro-3-
(trifluoromethyl)phenyl)isobutyramide).  The intractability of truncation mutants and the 
frequency of the agonist switch mutations suggest that novel ways, potentially LBD-independent 
ways, of targeting the AR are needed.  The design, synthesis and biological evaluation of these 
SARDs as putative treatments of Enz-R and other advanced PCs is discussed.  Moreover, these 
orally bioavailable SARDs are dual acting agents, i.e., potent inhibitors and degraders of AR, 
providing a higher evolutionary barrier to the development of resistance to II and III. For all 
these reasons, we believe that N-terminally directed SARDs28 may provide a next generation of 
AR antagonists to treat a variety of refractory and/or advanced prostate cancers, including Enz-
R, castration resistant, and/or AR-V7 dependent PCs which are not amendable with current 
hormone therapies.  As such, SARDs may delay the need to rely solely on chemotherapy.   
The lack of satisfactory hormonal pharmacotherapy for metastatic patients that have 
failed to respond to abiraterone and/or 5 and 6 [approved in February 2018] has piqued interest 
in the development of therapies to overcome Enz-R AR mutations.  Some of the promising 
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preclinical approaches include:  1.)  combination therapies, e.g.,  sorafenib55 or CDK-4/6 
inhibitors56 with 5 to revert the Enz-R phenotype; or   2.)  AR-directed monotherapies such as the 
emerging PROTACs technology that exploits cellular quality control machinery to selectively 
degrade specific target proteins57-58 by creating in this case AR-PROTAC-E3 ubiquitin ligase 
ternary complexes; or  3.)  AR-independent approaches to treat CRPC, e.g., by activating Natural 
Killer (NK) cells to attack the cancer59 ;  and each have shown promise in Enz-R or AR-V7 
CRPC preclinical models.  These approaches are still early in their development cycles, and 
many technical and regulatory hurdles remain for these approaches before any might reach the 
clinic for Enz-R patients.  Other drugs in the clinical pipeline such as second generation 
antiandrogens, e.g., darolutamide (OEM-201)60 , are just LBD-directed antiandrogens like 5 that 
will be susceptible to single amino acid and truncation escape mutations as observed for 5 and 6 
and all first generation antiandrogens.  Further, in the final analysis, none of the above may be 
approved which would leave no viable alternatives to taxanes in antiandrogen resistant CPRC.   
Importantly, to date none of the approaches mentioned above are dual targeted 
antagonists capable of inhibiting and destroying various FL and SV ARs including all escape 
mutants tested to date.  Herein we report for the first time, an initial SAR series for our SARD 
program for the indole (II) and indoline (III) SARDs described above that are capable of 
destroying FL and SV ARs with high efficacy.  Herein and recently,28 we characterized several 
members of groups I-III as having a unique biological activity profile optimized to address Enz-
R CPRC.  E.g., these compounds: 
1) Generally bind to LBD of wt AR; 
2) Inhibit transcriptional activation of wt AR (Tables 1, 3, and 4), escape mutant ARs 
(F876L in Figure 4A, and T877A, Q711A, L704A, and N705A), and SV AR;28  
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3) Exert high efficacy and potency SARD activity against FL and SV AR whether 
wildtype or harboring point-mutations (LNCaP in Tables 1, 3, and 4) or truncations 
(22RV1 in Tables 1, 3, and 4; LNCaP-95 and D567es cells28), including an Enz-R 
cellular context (e.g., MR49F in Figure 4B); 
4) Exert AR antagonism in vivo when administered orally in intact animals (Figure 7A); 
5) Exert PC anti-proliferative activity in vitro (Figure 5) and in vivo (see LNCaP, 
22RV1, and Pr-3001 xenografts28) including in Enz-R CRPC (Figure 7B); and 
6) Bind to a secondary binding site in AF-1 believed to mediate SARD activity as 
demonstrated in Supplemental Figure S2 for 19b by fluorescence polarization and for 
3 and 7 by fluorescence polarization and NMR studies.28  
This broad spectrum of androgen antagonism is itself unprecedented.  It is not possible at present 
to definitively assert that SARD activity alone is responsible for the activity seen in Enz-R cells 
and tumors.  E.g., SARD activity in vitro does not necessarily correlate with in vivo AR 
antagonism as seen with 19b vs. 19f where 19b would be the in vitro lead candidate and 19f 
would be the in vivo lead candidate.  We tested both and found equivocal Enz-R xenograft 
efficacy, leaving this an open question.   Though I-III suffer from a lack of metabolic stability in 
MLM, it was still possible to observe in vivo antagonism in mice in the seminal vesicles weight 
(an androgenic target organ) and in Enz-R xenografts.  Given the poor DMPK properties of II 
and III, we believe that additional SAR exploration to further co-optimize the SARD/antagonism 
and DMPK properties will reveal an even more promising in vivo pharmacodynamic profile.  
Further, it is our belief that this pharmacodynamic profile will be more resilient to the 
development of resistance, because: 
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1) SARD activity is effective against a variety of FL point mutations and SV AR truncations 
which lack the LBD, hence the development of resistance by these mechanisms may be 
thwarted or greatly delayed; 
2) SARD activity is mediated through a binding site in the NTD, further indicating that SV 
and LBD point mutations will not prevent SARD activity; 
3) SARD activity should be able to overcome resistance due to AR gene amplifications or 
intratumoral androgen synthesis by eliminating the binding site for endogeneous 
androgens; 
4) These agents are also potent antagonists of FL and SV transcriptional activations, 
allowing inhibition of any residual AR left due to incomplete AR degradation and/or the 
emergence of novel types of resistance to the SARD activity. 
Although Enz-R is the initial target population, these agents may also be promising in early stage 
PC because of the multiple barriers to the development of resistance.  The optimization of this 
template and the exploration of other templates of NTD-directed SARDs is ongoing, with 
improved bioavailabilities seen in other templates (to be published separately).  Cumulatively, it 
is our belief that NTD-directed SARDs, because of their unique mechanism and broad scope 
biological activity profile may be able to resurrect the AR-axis as a viable target, even after 
current antiandrogens have been tried and failed.  
 
4. EXPERIMENTAL SECTION  
General Chemistry Methods.  All chemicals for synthesis were purchased from Sigma-
Aldrich Chemical Co., Fisher Scientific (Pittsburgh, PA), Matrix Scientific (Columbia, SC), AK 
Scientific (Mountain View, CA), Oakwood Products (West Columbia, SC) etc. and used without 
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further purification. Moisture-sensitive reactions were carried under an argon atmosphere. 
Analytical thin-layer chromatography (TLC) was carried out on pre-coated silica gel (Merck 
Kieselgel 60 F254 layer thickness 0.25 mm). NMR spectra were obtained on a Bruker Avance III 
400 (Billerica, MA) spectrometer. Chemical shifts are reported as parts per million (ppm) 
relative to TMS in CDCl3 or DMSO-d6. The structure of synthesized compounds was also 
assigned by 1H-1H 2D-COSY and 2D-NOE NMR analytic methods. Flash column 
chromatography was performed on using silicagel (230-400 mesh, Merck). Mass spectral data 
was collected on a Bruker Esquire-LC/MS system (Bruker Daltonics, Billerica, MA) equipped 
with electrospray/ion trap instrument in positive and negative ion modes (ESI source). The purity 
of the final compounds was analyzed by an Agilent 1100 HPLC system (Santa Clara, CA). 
HPLC conditions: 45% acetonitrile at flow rate of 1.0 mL/min using a LUNA 5  C18 100A 
column (250 × 4.60 mm) purchased from Phenomenex (Torrance, CA) at ambient temperature. 
UV detection was set at 340 nm or 245 nm. Purities of the compounds were established by 
careful integration of areas for all peaks detected and determined as ≥95% for all compounds 
tested for biological study.  
General Procedure: Method A (for Class II indole derivatives, 18a ~ 18q, 19a ~ 19g). 
Under argon atmosphere, NaH of 60% dispersion in mineral oil (228 mg, 5.7 mmol) was added 
in 30 mL of anhydrous THF solution of substituted indole 16 (2.84 mmol) in 100 mL dried two 
necked round bottom flask equipped with a dropping funnel at ice-water bath, and the resulting 
solution was stirred 30 min at the ice-water bath (Scheme 1). Into the flask, the prepared solution 
of epoxide 14 or 15 (2.84 mmol in THF) was added through dropping funnel under argon 
atmosphere at the ice-water bath and stirred overnight at room temperature. After adding 1 mL of 
H2O, the reaction mixture was condensed under reduced pressure, and then dispersed into 50 mL 
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of EtOAc, washed with 50 mL (x 2) water, evaporated, dried over anhydrous MgSO4, and 
evaporated to dryness. The mixture was purified with flash column chromatography as an eluent 
EtOAc / hexane to produce the desired indole series II.  
General Procedure: Method B (for Class III indoline derivatives, 20a ~ 20g, 21a ~ 
21f).  Under argon atmosphere, 2.0 M lithium diisopropylamide solution (4.6 mL, 4.6 mmol) in 
THF/heptane/ethylbenzene was slowly added in a dropwise manner over 10 min to a solution of 
substituted indoline 17 (2.2 mmol) in 5 mL of anhydrous THF at -78 oC and warmed to 0 oC and 
stirred for 10 min and cooled again to -78 oC (Scheme 1).  To the solution was added in a 
dropwise fashion to a solution of epoxide 14 or 15 (2.2 mmol) prepared from compounds 12 or 
13, and the reaction mixture was stirred for overnight. After quenching by addition of sat. 
NH4Cl, the solution was concentrated under reduced pressure and dispersed into excess EtOAc 
and dried over Na2SO4. The solution was concentrated and purified by flash column 
chromatography (EtOAc/hexane or DCM/hexane) to give the desired indoline series compound 
of III. 
Synthesis and Analysis of Compounds.  Preparation of a solution of (S)-N-aryl-2-
methyloxirane-2-carboxamide (14 or 15): A mixture of hydroxylbromide 12 or 13 (2.84 mmol) 
and potassium carbonate (5.70 mmol) in 60 mL acetone was heated to reflux for 30 min. After 
complete conversion of starting bromide 12 or 13 to desired intermediate epoxide 14 or 15 as 
monitored by TLC, the solvent was evaporated under reduced pressure to give yellowish residue, 
which was poured into 20 mL of anhydrous EtOAc (Scheme 1). The solution was filtered through 
Celite pad to remove K2CO3 residue and condensed under reduced pressure to give a yellowish 
solid of epoxide, which was dissolved in 5 mL of anhydrous THF to prepare a desired solution of 
epoxide in THF. The resulting solution was directly used as next reactant without analysis 
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(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide (14).  
Light yellowish solid. Yield = 95%; MS (ESI) m/z 269.5 [M – H] -; 1H NMR (CDCl3, 400 MHz) 
 8.68 (bs, 1H, NH), 8.10 (s, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 3.02 (d, J = 
4.8 Hz, 1H), 2.98 (d, J = 4.8 Hz, 1H), 1.65 (s, 3H); 19F NMR (CDCl3, decoupled)  -62.23.   
(S)-N-(3-Chloro-4-cyanophenyl)-2-methyloxirane-2-carboxamide (15).  Yield = 
92% ; MS (ESI) m/z 316.86 [M – H] -; 1H NMR (CDCl3, 400 MHz)  8.86 (bs, 1H), 7.97 (d, J = 
2.0 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.54 (dd, J = 8.8, 2.0 Hz, 1H), 4.02 (d, J = 10.8 Hz, 1H), 
3.60 (d, J = 10.8 Hz, 1H), 2.99 (s, OH, 1H), 1.58 (s, 3H); 13C NMR (CDCl3, 100 MHz)  171.3, 
141.8, 138.0, 120.3, 117.7, 115.9, 108.6, 75.5, 41.2, 24.8. 
5-Fluoro-6-phenyl-1H-indole (16a).  To a suspension of 
tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4, 0.54 g, 0.467 mmol] in 20 mL of ethylene 
glycol dimethyl ether (DME) was added 6-bromo-5-fluoroindole (1.00 g, 4.67 mmol), and the 
mixture was stirred for 15 minutes under argon at room temperature. A solution of 
phenylboronic acid (0.57 g, 4.67 mmol) in 2-3 mL of ethanol was added and the mixture was 
stirred for 10 minutes under the same conditions. A solution of potassium carbonate (0.97 g, 7.01 
mmol) in 2 mL of water was added to the above mixture and the resulting reaction mixture was 
heated at reflux for 3-4 h under the argon atmosphere. The end of the reaction was established by 
TLC. The reaction was diluted by brine, and extracted with ethyl acetate. The organic layer was 
washed with brine, dried with MgSO4, filtered, and concentrated under vacuum. The product was 
purified by a silica gel column using ethyl acetate and hexanes (1:3, v/v) as an eluent to afford 
0.90 g (yield 92%) of the titled compound as light brown solid. 
4-Phenyl-1H-indole (16b).  To a suspension of tetrakis(triphenylphosphine)palladium(0) 
[Pd(PPh3)4, 1.179 g, 1.0212 mmol] in 40 mL of ethylene glycol dimethyl ether (DME) was 
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added 4-bromo-indole (2.00 g, 10.202 mmol), and the mixture was stirred for 15 minutes under 
argon at room temperature. A solution of phenylboronic acid (1.24 g, 10.202 mmol) in 4.5 mL of 
ethanol was added and the mixture was stirred for 10 minutes under the same conditions. A 
solution of potassium carbonate (2.16 g, 15.306 mmol) in 3.5 mL of water was added to the 
above mixture and the resulting reaction mixture was heated at reflux for 3-4 h under the argon 
atmosphere. After the end of the reaction was established by TLC, the reaction was diluted by 
brine, and extracted with ethyl acetate. The organic layer was washed with brine, dried with 
MgSO4, filtered, and concentrated under vacuum. The product was purified by a silica gel 
column using ethyl acetate and hexane (1:3 to 2:1, v/v) as eluent to afford 1.67 g (yield 84.8%) 
of the titled compound as yellowish oil. 
4-Fluoro-6-(4-fluorophenyl)-1H-indole (16c).  To a suspension of 
tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4, 270 mg, 0.2336 mmol] in 10 mL of 
ethylene glycol dimethyl ether (DME) was added 6-bromo-4-fluoro-indole (0.50 g, 2.336 mmol), 
and the mixture was stirred for 15 minutes under argon at room temperature. A solution of 4-
fluoro-phenylboronic acid (0.33 g, 2.336 mmol) in 1.2 mL of ethanol was added and the mixture 
was stirred for 10 minutes under the same conditions. A solution of potassium carbonate (0.48 g, 
3.504 mmol) in 1.0 mL of water was added to the above mixture and the resulting reaction 
mixture was heated at reflux for 3-4 h under argon atmosphere. After the end of the reaction was 
established by TLC, the reaction was diluted by brine, and extracted with ethyl acetate. The 
organic layer was washed with brine, dried with MgSO4, filtered, and concentrated under 
vacuum. The product was purified by a silica gel column using ethyl acetate and hexane (1:3, 
v/v) as an eluent to afford 0.33 g (yield 61.6%) of the titled compound as brown solid. 
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(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-3-(1H-indol-1-yl)-2-
methylpropanamide (18a).  By Method A: Yield 55%; Light brown solid; MS (ESI) m/z 358.9 
[M - H] -; 1H NMR (CDCl3, 400 MHz)  8.67 (bs, 1H, NH), 7.96 (dd, J = 8.4, 2.0 Hz, 1H), 7.80 
(s, 1H), 7.71-7.65 (m, 2H), 7.51 (d, J = 8.0 Hz, 1H),  7.35 (d, J = 8.0 Hz, 1H), 7.12 (t, J = 8.0 Hz, 
1H), 7.02 (m, 1H), 6.45 (d, J = 3.2 Hz, 1H), 4.58 (d, J = 14.8 Hz, 1H), 4.30 (d, J = 14.8 Hz, 1H), 
2.50 (bs, 1H, OH), 1.54 (s, 3H).   
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-fluoro-1H-indol-1-yl)-2-hydroxy-2-
methylpropanamide (18b).  By Method A: Yield 49%; White solid; MS (ESI) m/z 404.1 [M - 
H] -; 1H NMR (CDCl3, 400 MHz)  8.78 (bs, 1H, NH), 7.92 (s, 1H), 7.78 (m, 2H), 7.23 (d, J = 
8.0 Hz, 1H), 7.14-7.11 (m, 2H), 6.78 (dd, J = 10.0, 2.0 Hz, 1H), 6.63 (d, J = 2.8 Hz, 1H), 4.67 (d, 
J = 14.8 Hz, 1H), 4.39 (d, J = 14.8 Hz, 1H), 2.60 (bs, 1H, OH), 1.65 (s, 3H).   
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(6-fluoro-1H-indol-1-yl)-2-hydroxy-2-
methylpropanamide (18c).  By Method A: Yield 48%; White solid; MS (ESI) m/z 404.0 [M - 
H] -; 1H NMR (CDCl3, 400 MHz)  8.79 (bs, 1H, NH), 7.89 (d, J = 1.6 Hz, 1H), 7.83 (d, J = 8.4 
Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.51 (dd, J = 8.4, 5.2 Hz, 1H), 7.14 (dd, J = 10.0, 2.0 Hz, 1H), 
7.11 (d, J = 3.2 Hz, 1H), 6.87 (dt, J = 8.8, 2.0 Hz, 1H), 6.51 (d, J = 3.2 Hz, 1H), 4.62 (d, J = 14.8 
Hz, 1H), 4.32 (d, J = 14.8 Hz, 1H), 2.56 (bs, 1H, OH), 1.65 (s, 3H).   
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-3-(5-nitro-1H-indol-
1-yl)propanamide (18e).  By Method A: Yield 47%; Yellowish solid; MS (ESI): 431.0 [M – H] 
-; 1H NMR (Acetone-d6, 400 MHz)  9.68 (bs, 1H, NH), 8.35 (d, J = 2.0 Hz, 1H), 8.16 (s, 1H), 
8.01 (m, 1H), 7.88-7.81 (m, 2H), 7.58 (d, J = 8.8 Hz, 1H), 7.38 (d, J = 3.4 Hz, 1H), 6.58 (d, J = 
3.4 Hz, 1H), 5.49 (s, 1H, OH), 4.66 (d, J = 14.8 Hz, 1H), 4.38 (d, J = 14.8 Hz, 1H), 1.50 (s, 3H).  
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(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-3-(6-nitro-1H-indol-
1-yl)propanamide (18f).  By Method A: Yield 31%; MS (ESI) m/z 431.1 [M – H] –; 1H NMR 
(400 MHz, CDCl3) δ 8.87 (bs, 1H, NH), 8.53 (m, 1H), 8.01 (dd, J = 8.8, 2.0 Hz, 1H), 7.92 (d, J = 
2.0 Hz, 1H), 7.86 (dd, J = 8.4, 2.0 Hz, 1H),  7.78 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 
7.43 (d, J = 3.0 Hz, 1H), 6.61 (d, J = 3.0 Hz, 1H), 4.76 (d, J = 14.8 Hz, 1H), 4.48 (d, J = 14.8 Hz, 
1H), 3.14 (s, 1H, OH), 1.74 (s, 3H).  
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(5-fluoro-3-methyl-1H-indol-1-yl)-2-
hydroxy-2-methylpropanamide (18g).  By Method A: Yield 64%; MS (ESI) m/z 418.1 [M – H] 
-; 1H NMR (400 MHz, CDCl3) δ 8.85 (bs, 1H, NH), 7.86 (m, 1H), 7.81-7.74 (m, 2H),  7.29 (dd, J 
= 9.0, 4.0 Hz, 1H), 7.14 (dd, J = 9.0, 2.4 Hz, 1H), 6.92 (m, 2H), 4.60 (d,  J = 15.2 Hz, 1H), 4.27 
(d,  J = 15.2 Hz, 1H), 2.22 (s, 3H), 1.57 (s, 3H). 
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(5-fluoro-6-phenyl-1H-indol-1-yl)-2-
hydroxy-2-methylpropanamide (18i).  By Method A: To a solution of 5-fluoro-6-phenyl-1H-
indole (16a, 370 mg, 1.75 mmol) in anhydrous THF (10 mL), which was cooled in an ice water 
bath under an argon atmosphere, was added sodium hydride (60% dispersion in oil, 0.11 g, 2.63 
mmol). After addition, the resulting mixture was stirred for three hours. (S)-N-(4-Cyano-3-
(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide (14, 470 mg, 2.175 mmol) was added 
to above solution, and the resulting reaction mixture was allowed to stir overnight at room 
temperature under argon. The reaction was quenched by water, and extracted with ethyl acetate. 
The organic layer was washed with brine, dried with MgSO4, filtered, and concentrated under 
vacuum. The product was purified by a silica gel column using ethyl acetate and hexane (1:2, 
v/v) as eluent to afford 830 mg (yield 98%) of the titled compound as off-white foam.  1H NMR 
(400 MHz, DMSO-d6) δ 10.29 (s, 1H, NH), 8.28 (s, 1H, ArH), 8.08 (d, J = 8.8 Hz, 1H, ArH), 
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7.96 (d, J = 8.8 Hz, 1H, ArH), 7.58 (d, J = 6.8 Hz, 1H, ArH), 7.49-7.31 (m, 7H, ArH), 6.42 (d, J 
= 3.2 Hz, 1H, ArH), 6.35 (s, 1H, OH), 4.61 (d, J = 14.4 Hz, 1H, CH), 4.35 (d, J = 14.4Hz, 1H, 
CH), 1.46 (s, 3H, CH3).  
(S)-3-(5-Bromo-1H-indol-1-yl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-
methylpropanamide (18j).  By Method A: Yield 71%;  MS (ESI) 465.1 [M - H] -; 1H NMR 
(CDCl3, 400 MHz)  8.73 (bs, 1H, NH), 7.88 (s, 1H), 7.74 (d, J = 1.8 Hz, 1H), 7.69 (d, J = 1.8 
Hz, 1H), 7.30 (d, J = 8.8 Hz, 1H), 7.24 (m, 1H), 7.24 (dd, J = 8.8, 2.0 Hz, 1H), 7.13 (d, J = 3.2 
Hz, 1H), 6.45 (d, J = 3.2 Hz, 1H),  4.39 (d, J = 14.8 Hz, 1H), 2.60 (bs, 1H, OH), 1.65 (s, 3H).   
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-3-(5-iodo-1H-indol-1-yl)-2-
methylpropanamide (18k).  By Method A: Yield 74%; MS (ESI) m/z 511.9 [M - H] -; 1H NMR 
(CDCl3, 400 MHz)  8.71 (bs, 1H, NH), 7.91 (d, J = 1.6 Hz, 1H), 7.74 (m, 2H), 7.43 (dd, J = 8.8, 
1.6 Hz, 1H), 7.21 (d, J = 8.8 Hz, 1H), 7.08 (d, J = 3.2 Hz, 1H), 6.44 (d, J = 3.2 Hz, 1H), 4.62 (d, 
J = 15.0 Hz, 1H), 4.32 (d, J = 15.0 Hz, 1H), 2.44 (bs, 1H, OH), 1.61 (s, 3H).   
(S)-Ethyl 1-(3-((4-cyano-3-(trifluoromethyl)phenyl)amino)-2-hydroxy-2-methyl-3-
oxopropyl)-1H-indole-3-carboxylate (18m).  By Method A: Yield 92%; MS (ESI) m/z 458.1 
[M – H] -; 482.4 [M + Na] + ; 1H NMR (400 MHz, CDCl3) δ 8.86 (bs, 1H, NH), 8.00 (m, 2H), 
7.81 (s, 1H), 7.65 (s, 2H), 7.46 (d,  J = 8.0 Hz, 1H), 7.24-7.18 (m, 2H), 4.65 (d,  J = 14.4 Hz, 
1H), 4.39 (d,  J = 14.4 Hz, 1H), 4.36 (bs, 1H, OH), 4.23-4.11 (m, 2H), 1.66 (s, 3H), 1.35 (t,  J = 
7.2 Hz, 3H). 
(S)-3-(5-Cyano-1H-pyrrolo[3,2-b]pyridin-1-yl)-N-(4-cyano-3-
(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (18n).  By Method A: Yield 67%; 
White solid ; MS (ESI) m/z 412.1 [M – H] -; 436.1 [M + Na] +; 1H NMR (400 MHz, Acetone-d6) 
δ 9.84 (bs, 1H, NH), 8.31 (s, 1H), 8.14 (m, 2H), 8.01 (m, 1H), 7.81 (d,  J = 2.8 Hz, 1H), 7.60 (d,  
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J = 8.4 Hz, 1H), 6.67 (d,  J = 2.8 Hz, 1H), 5.64 (bs, 1H), 4.84 (d,  J = 14.8 Hz, 1H), 4.52 (d,  J = 
14.8 Hz, 1H), 1.66 (s, 3H). 
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-3-(4-phenyl-1H-
indol-1-yl)propanamide (18o).  By Method A: To a solution of 4-phenyl-1H-indole (16b, 0.42 
g, 2.173 mmol) in anhydrous THF (10 mL), which was cooled in an ice water bath under an 
argon atmosphere, was added sodium hydride (60% dispersion in oil, 0.22 g, 5.434 mmol). After 
addition, the resulting mixture was stirred for three hours. (S)-N-(4-cyano-3-
(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide (14, 0.76 g, 2.173 mmol) was added to 
the above solution, and the resulting reaction mixture was allowed to stir overnight at room 
temperature under argon. The reaction was quenched by water, and extracted with ethyl acetate. 
The organic layer was washed with brine, dried with MgSO4, filtered, and concentrated under 
vacuum. The product was purified by a silica gel column using ethyl acetate and hexane (1:2, 
v/v) as eluent to afford 0.69 g (yield 69%) of the titled compound as off-white solid.  1H NMR 
(400 MHz, DMSO-d6)  10.37 (s, 1H, NH), 8.37 (d, J = 2.0 Hz, 1H, ArH), 8.18 (dd, J = 8.4 Hz, 
J = 2.0 Hz, 1H, ArH), 8.05 (d, J = 8.4 Hz, 1H, ArH), 7.60-7.54 (m, 3H, ArH), 7.49-7.45 (m, 2H, 
ArH), 7.38-7.34 (m, 2H, ArH), 7.18-7.14 (m, 1H, ArH), 7.04 (d, J = 7.2 Hz, 1H, ArH), 6.51 (d, J 
= 3.2 Hz, 1H, ArH), 6.35 (s, 1H, OH), 4.58 (d, J = 14.4 Hz, 1H, CH), 4.38 (d, J = 14.4 Hz, 1H, 
CH), 1.45 (s, 3H, CH3). MS (ESI, Positive) m/z 464.1536 [M + H] 
+; 486.1351 [M + Na] +. 
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-fluoro-5-phenyl-1H-indol-1-yl)-2-
hydroxy-2-methylpropanamide (18p).  By Method A: To a solution of 4-fluoro-5-phenyl-1H-
indole (330 mg, 0.00156mol) in anhydrous THF (10 mL), which was cooled in an ice water bath 
under an argon atmosphere, was added sodium hydride (60% dispersion in oil, 160 mg, 3.91 
mmol). After addition, the resulting mixture was stirred for three hours. (S)-N-(4-Cyano-3-
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(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide 14 (550 mg, 1. 56 mmol) was added to 
the above solution, and the resulting reaction mixture was allowed to stir overnight at room 
temperature under argon. The reaction was quenched by water, and extracted with ethyl acetate. 
The organic layer was washed with brine, dried with MgSO4, filtered, and concentrated under 
vacuum. The product was purified by a silica gel column using ethyl acetate and hexanes (1:2, 
v/v) as eluent to afford 470 mg (yield 63%) of the titled compound as off-white solid.  1H NMR 
(400 MHz, DMSO-d6)  10.33 (s, 1H, NH), 8.35 (d, J = 2.0 Hz, 1H, ArH), 8.17 (dd, J = 8.4, 2.0 
Hz, 1H, ArH), 8.05 (d, J = 8.4 Hz, 1H, ArH), 7.51-7.40 (m, 5H, ArH), 7.36-7.32 (m, 2H, ArH 
and indole-H), 7.17-7.13 (m, 1H, ArH), 6.53 (d, J = 3.2 Hz, 1H, ArH), 6.38 (s, 1H, OH), 4.60 (d, 
J = 14.8 Hz, 1H, CH), 4.38 (d, J = 14.8 Hz, 1H, CH), 1.45 (s, 3H, CH3); MS (ESI, Negative) m/z 
[M - H] -; (ESI, Positive): 482.1490 [M + H] +; 504.1310 [M + Na] +. 
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-fluoro-6-(4-fluorophenyl)-1H-indol-
1-yl)-2-hydroxy-2-methylpropanamide (18q).  By Method A: To a solution of 4-fluoro-6-(4-
fluoro-phenyl)-1H-indole (16c, 0.32 g, 1.4 mmol) in anhydrous THF (10 mL), which was cooled 
in an ice water bath under an argon atmosphere, was added sodium hydride (60% dispersion in 
oil, 0.17 g, 4.19 mmol). After addition, the resulting mixture was stirred for three hours. (S)-N-
(4-Cyano-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide (14, 0.49 g, 1.40 mmol) 
was added to the above solution, and the resulting reaction mixture was allowed to stir overnight 
at room temperature under argon. The reaction was quenched by water, and extracted with ethyl 
acetate. The organic layer was washed with brine, dried with MgSO4, filtered, and concentrated 
under vacuum. The product was purified by a silica gel column using ethyl acetate and hexanes 
(1:2, v/v) as eluent to afford 0.35 g (yield 50.5%) of the titled compound as off-white solid.  1H 
NMR (400 MHz, DMSO-d6)  10.30 (s, 1H, NH), 8.26 (d, J = 2.0 Hz, 1H, ArH), 8.07 (dd, J = 
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8.8 Hz, J = 2.0 Hz, 1H, ArH), 7.97 (d, J = 8.8 Hz, 1H, ArH), 7.68-7.64 (m, 2H, ArH), 7.60 (s, 
1H, ArH), 7.35 (d, J = 3.0 Hz, 1H, ArH), 7.28-7.24 (m, 2H, ArH)), 7.04 (dd, J = 12.0 Hz,  1.2 
Hz, 1H, ArH), 6.48 (d, J = 1.0 Hz, 1H, ArH), 6.39 (s, 1H, OH), 4.67 (d, J = 14.8 Hz, 1H, CH), 
4.42 (d, J = 14.8 Hz, 1H, CH), 1.49 (s, 3H, CH3); MS (ESI, Negative) m/z [M - H] 
-; (ESI, 
Positive) 499.2056 [M + H] +. 
(S)-N-(3-Chloro-4-cyanophenyl)-3-(3-fluoro-1H-indol-1-yl)-2-hydroxy-2-
methylpropanamide (19a).  By Method A: Yield 68%; Mp 168.9-170.1oC; Light brown solid; 
MS (ESI) m/z 369.8 [M - H] -; 1H NMR (CDCl3, 400 MHz)  8.66 (bs, 1H, NH), 7.81 (d, J = 2.0 
Hz, 1H), 7.60-7.56 (m, 2H), 7.37 (dd, J = 8.4, 2.0 Hz, 2H), 7.23 (m, 1H),  7.12 (t, J = 7.4 Hz, 
1H), 6.93 (d, J = 2.8 Hz, 1H), 4.56 (d, J = 15.2 Hz, 1H), 4.27 (d, J = 15.2 Hz, 1H), 2.44 (s, 1H, 
OH), 1.59 (s, 3H); 19F NMR (CDCl3, decoupled)  -173.91. 
(S)-N-(3-Chloro-4-cyanophenyl)-3-(4-fluoro-1H-indol-1-yl)-2-hydroxy-2-
methylpropanamide (19b).  By Method A: Yield 73%; White solid; MS (ESI) m/z 369.9 [M - 
H] -; 1H NMR (CDCl3, 400 MHz)  8.64 (bs, 1H, NH), 7.81 (s, 1H), 7.57 (d, J = 8.4 Hz, 1H), 
7.35 (d, J = 7.2 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 7.14-7.10 (m, 2H), 6.77 (t, J = 8.4 Hz, 1H), 
6.63 (d, J = 2.8 Hz, 1H), 6.60 (s, 1H), 4.64 (d, J = 14.8 Hz, 1H), 4.35 (d, J = 14.8 Hz, 1H), 2.48 
(bs, 1H, OH), 1.60 (s, 3H).  19F NMR (CDCl3, decoupled)  -121.78. 
(S)-N-(3-Chloro-4-cyanophenyl)-3-(5-fluoro-1H-indol-1-yl)-2-hydroxy-2-
methylpropanamide (19c).  By Method A: Yield 79%; White solid; MS (ESI) m/z 371.0 [M - 
H] -; 1H NMR (CDCl3, 400 MHz)  8.62 (bs, 1H, NH), 7.80 (d, J = 2.0 Hz, 1H), 7.56 (d, J = 8.4 
Hz, 1H), 7.38-7.34 (m, 2H), 7.23 (dd, J = 9.2, 2.4 Hz, 1H), 7.22 (dt, J = 9.2, 2.8 Hz, 1H), 7.15 (d, 
J = 3.2 Hz, 1H), 6.47 (d, J = 3.2 Hz, 1H), 4.63 (d, J = 14.8 Hz, 1H), 4.32 (d, J = 14.8 Hz, 1H), 
2.49 (bs, 1H, OH), 1.60 (s, 3H); 19F NMR (CDCl3, decoupled)  -124.52. 
42 
 
(S)-N-(3-Chloro-4-cyanophenyl)-3-(6-fluoro-1H-indol-1-yl)-2-hydroxy-2-
methylpropanamide (19d).  By Method A: Yield 67%; White solid; MS (ESI) m/z 376.9 [M - 
H] -; 1H NMR (CDCl3, 400 MHz)  8.67 (bs, 1H, NH), 7.79 (d, J = 2.0 Hz, 1H), 7.56 (d, J = 8.4 
Hz, 1H), 7.49 (dd, J = 8.4, 5.4 Hz, 1H), 7.38 (dd, J = 8.4, 2.0 Hz, 1H), 7.13 (dd, J = 10.0, 2.0 Hz, 
1H), 7.09 (d, J = 3.2 Hz, 1H), 6.86 (m, 2H), 6.48 (d, J = 3.2 Hz, 1H), 4.58 (d, J = 14.8 Hz, 1H), 
4.28 (d, J = 14.8 Hz, 1H), 2.61 (bs, 1H, OH), 1.60 (s, 3H); 19F NMR (CDCl3, decoupled)  -
120.03. 
(S)-N-(3-Chloro-4-cyanophenyl)-3-(7-fluoro-1H-indol-1-yl)-2-hydroxy-2-
methylpropanamide (19e).  By Method A: Yield 73%; White solid; MS (ESI) m/z 370.0 [M - 
H] -; 1H NMR (CDCl3, 400 MHz)  8.82 (d, J = 2.0 Hz, 1H), 8.60 (bs, 1H, NH), 7.55 (d, J = 8.4 
Hz, 1H), 7.37-7.34 (m, 2H), 7.02 (d, J = 3.2 Hz, 1H), 7.00 (m, 1H), 7.01-6.98 (m, 1H), 6.91 (m, 
1H), 6.46 (t, J = 2.8 Hz, 1H), 4.68 (d, J = 15.0 Hz, 1H), 4.62 (d, J = 15.0 Hz, 1H), 2.73 (d, J = 
4.4 Hz, 1H, OH), 1.61 (s, 3H); 19F NMR (CDCl3, decoupled)  -133.54. 
(S)-N-(3-Chloro-4-cyanophenyl)-3-(5-fluoro-6-phenyl-1H-indol-1-yl)-2-hydroxy-2-
methylpropanamide (19f).  By Method A: To a solution of 5-fluoro-6-phenyl-1H-indole (16a, 
0.20 g, 0.947 mmol) in anhydrous THF (10 mL), which was cooled in an ice water bath under an 
argon atmosphere, was added sodium hydride (60% dispersion in oil, 0.076 g, 1.89 mmol). After 
addition, the resulting mixture was stirred for three hours. (R)-3-Bromo-N-(4-cyano-3-chloro-
phenyl)-2-hydroxy-2-methylpropanamide (13, 0.30 g, 0.947 mmol) was added to above solution, 
and the resulting reaction mixture was allowed to stir overnight at room temperature under 
argon. The reaction was quenched by water, and extracted with ethyl acetate. The organic layer 
was washed with brine, dried with MgSO4, filtered, and concentrated under vacuum. The product 
was purified by a silica gel column using ethyl acetate and hexane (1:2, v/v) as eluent to afford 
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0.26 g of the titled compound as yellowish solid. Yield = 76%; 1H NMR (400 MHz, DMSO-d6) δ 
10.11 (s, 1H, NH), 8.04 (d, J = 1.6 Hz, 1H, ArH), 7.80 (d, J = 8.8 Hz, 1H, ArH), 7.74 (dd, J = 8.2 
Hz, J = 2.0 Hz, 1H, ArH), 7.62 (d, J = 6.4 Hz, 1H, ArH), 7.51-7.44 (m, 4H, ArH), 7.39-7.32 (m, 
3H, ArH), 6.42 (d, J = 3.2 Hz, 1H, ArH), 6.33 (s, 1H, OH), 4.60 (d, J = 15.2 Hz, 1H, CH), 4.35 
(d, J = 15.2 Hz, 1H, CH), 1.45 (s, 3H, CH3).  MS (ESI, Negative) m/z 445.8 [M - H] 
-; (ESI, 
Positive) m/z 470.0 [M + Na] +. 
(S)-N-(3-Chloro-4-cyanophenyl)-3-(5-fluoro-3-phenyl-1H-indol-1-yl)-2-hydroxy-2-
methylpropanamide (19g).  By Method A: To a solution of 5-fluoro-3-phenyl-1H-indole (500 
mg, 2.267 mmol) in anhydrous THF (10 mL), which was cooled in an ice water bath under an 
argon atmosphere, was added sodium hydride (60% dispersion in oil, 240 mg, 5.918 mmol). 
After addition, the resulting mixture was stirred for three hours. (R)-3-Bromo-N-(4-cyano-3-
chloro-phenyl)-2-hydroxy-2-methylpropanamide (13, 0.75 g, 2.267 mmol) was added to the 
above solution, and the resulting reaction mixture was allowed to stir overnight at room 
temperature under argon. The reaction was quenched by water, and extracted with ethyl acetate. 
The organic layer was washed with brine, dried with MgSO4, filtered, and concentrated under 
vacuum. The product was purified by a silica gel column using ethyl acetate and hexane (1:2 to 
1:1, v/v) as eluent to afford 0.43 g of the titled compound as yellowish solid.  Yield = 85%; 1H 
NMR (400 MHz, DMSO-d6) 10.17 (s, 1H, NH), 8.06 (d, J = 2.0 Hz, 1H, ArH), 7.86-7.79 (m, 
2H, ArH), 7.64 (s, 1H, ArH), 7.62-7.58 (m, 1H, ArH), 7.55-7.52 (m, 2H, ArH), 7.50 (dd, J = 
10.4 Hz, J = 2.4 Hz, 1H, ArH), 7.43-7.40 (m, 2H, ArH), 7.26-7.22 (m, 1H, ArH), 7.03-6.98 (m, 
1H, ArH), 6.37 (s, 1H, OH), 4.60 (d, J = 14.8 Hz, 1H, CH), 4.38 (d, J = 14.8 Hz, 1H, CH), 1.46 
(s, 3H, CH3). MS (ESI, Negative) m/z 446.8 [M – H] -; (ESI, Positive) m/z 448.1248 [M + H] +. 
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(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-3-(indolin-1-yl)-2-
methylpropanamide (20a).  By Method B: Yield 71%; MS (ESI) 387.8 [M – H] –;1H NMR 
(400 MHz, CDCl3) δ 9.24 (bs, 1H, NH), 8.09 (d, J = 2.0 Hz, 1H), 7.94 (dd, J = 8.4, 2.0 Hz, 1H), 
7.78 (d, J = 8.4 Hz, 1H), 7.13-7.08 (m, 2H), 6.78 (d, J = 7.8, 0.8 Hz, 1H), 6.62 (d, J = 7.8, 0.8 
Hz, 1H), 3.78 (s, 1H, OH), 3.66 (d, J = 14.4 Hz, 1H), 3.54 (t, J = 8.4 Hz, 1H), 3.46-3.40 (m, 1H), 
3.32 (d, J = 14.4 Hz, 1H), 3.30 (m, 1H), 3.05-2.94 (m, 2H), 1.57 (s, 3H).  
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-fluoroindolin-1-yl)-2-hydroxy-2-
methylpropanamide (20b).  By Method B: Yield 75%; MS (ESI) m/z 406.0 [M – H] –; 1H NMR 
(400 MHz, CDCl3) δ 9.24 (bs, 1H, NH), 8.10 (d, J = 2.2 Hz, 1H), 7.95 (dd, J = 8.8, 2.2 Hz, 1H), 
7.79 (d, J = 8.8 Hz, 1H), 6.83 (dd, J = 8.4, 2.4 Hz, 1H), 6.77 (m. 1H), 6.52 (dd, J = 8.4, 4.0 Hz, 
1H), 3.75 (bs, 1H, OH), 3.64 (d, J = 14.0 Hz, 1H), 3.44 (m, 1H), 3.30 (q, J = 9.2 Hz, 1H), 3.22 
(d,  J = 14.0 Hz, 1H), 2.94 (m, 2H), 1.56 (s, 3H).  
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(6-fluoroindolin-1-yl)-2-hydroxy-2-
methylpropanamide (20e).  By Method B: Yield 47%; MS (ESI) m/z 405.9 [M – H] –; 1H NMR 
(400 MHz, CDCl3) δ 9.05 (bs, 1H, NH), 7.98 (d, J = 2.4 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.53 
(dd, J = 8.4, 2.1 Hz, 1H), 7.04 (m, 1H), 6.48 (t, J = 8.4 Hz, 1H), 6.39 (d, J = 8.0 Hz, 1H), 3.68 (d, 
J = 14.4 Hz, 1H), 3.50 (bs, 1H, OH), 3.37 (q, J = 9.2 Hz, 1H), 3.29 (d, J = 14.02 Hz, 1H), 3.09 
(m, 1H), 2.97 (m, 1H), 1.55 (s, 3H).  
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(5,6-difluoroindolin-1-yl)-2-hydroxy-2-
methylpropanamide (20f).  By Method B: Yield 59%; MS (ESI) m/z 424.07 [M – H] –; 426.06 
[M + H] +; 1H NMR (400 MHz, CDCl3) δ 9.18 (bs, 1H, NH), 8.09 (d, J = 2.0 Hz, 1H), 7.97 (dd, J 
= 8.4, 2.0 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 6.89 (t, J = 8.8 Hz, 1H), 6.43 (m, 1H), 3.64 (d, J = 
14.4 Hz, 1H), 3.46 (s, 1H, OH), 3.40-3.35 (m, 2H), 3.17 (d, J = 14.4 Hz, 1H), 2.99-2.91 (m, 2H), 
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1.57 (s, 3H), 19F NMR (CDCl3, decoupled) δ -62.21 (CF3), -139.18 (d, JF-F = -21.6 Hz, Ar-F), -
150.28 (d, JF-F = -21.6 Hz, Ar-F).  
(S)-3-(5-Chloro-6-fluoroindolin-1-yl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-
hydroxy-2-methylpropanamide (20g).  By Method B:  Yield 47%; MS (ESI) m/z 440.3 [M – 
H] –; 1H NMR (400 MHz, CDCl3) δ 9.15 (bs, 1H, NH), 8.02 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 8.4 
Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 6.42 (d, J = 10.0 Hz, 1H), 3.66 (d, J = 14.4 Hz, 1H), 3.52-3.42 
(m, 2H), 3.38 (s, 1H, OH), 3.21 (d, J = 14.4 Hz, 1H), 2.96-2.80 (m, 2H), 1.52 (s, 3H).  
(S)-N-(3-Chloro-4-cyanophenyl)-3-(4-fluoroindolin-1-yl)-2-hydroxy-2-
methylpropanamide (21a).  By Method B: Yield 71%; MS (ESI) m/z 372.0 [M – H] –; []20D -
173o (c 1.0, CH3OH); 
1H NMR (400 MHz, CDCl3) δ 9.05 (bs, 1H, NH), 7.98 (d, J = 2.4 Hz, 1H), 
7.62 (d, J = 8.4 Hz, 1H), 7.53 (dd, J = 8.4, 2.1 Hz, 1H), 7.04 (m, 1H), 6.48 (t, J = 8.4 Hz, 1H), 
6.39 (d, J = 8.0 Hz, 1H), 3.68 (d, J = 14.4 Hz, 1H), 3.50 (bs, 1H, OH), 3.37 (q, J = 9.2 Hz, 1H), 
3.29 (d, J = 14.2 Hz, 1H), 3.09 (m, 1H), 2.97 (m, 1H), 1.55 (s, 3H).  
(S)-N-(3-Chloro-4-cyanophenyl)-3-(5-fluoroindolin-1-yl)-2-hydroxy-2-
methylpropanamide (21b).  By Method B: Yield 64%; MS (ESI) m/z 372.0 [M – H] – ; [ ]D20 = 
-202 o; 1H NMR (400 MHz, CDCl3) δ 9.05 (bs, 1H, NH), 7.98 (d, J = 2.4 Hz, 1H), 7.62 (d, J = 
8.4 Hz, 1H), 7.53 (dd, J = 8.4, 2.1 Hz, 1H), 7.04 (m, 1H), 6.48 (t, J = 8.4 Hz, 1H), 6.39 (d, J = 
8.0 Hz, 1H), 3.68 (d, J = 14.4 Hz, 1H), 3.50 (bs, 1H, OH), 3.37 (q, J = 9.2 Hz, 1H), 3.29 (d, J = 
14.2 Hz, 1H), 3.09 (m, 1H), 2.97 (m, 1H), 1.55 (s, 3H).  
(S)-3-(5-Bromoindolin-1-yl)-N-(3-chloro-4-cyanophenyl)-2-hydroxy-2-
methylpropanamide (21c).  By Method B: Yield 54%; MS (ESI) m/z 433.6 [M – H] –; 1H NMR 
(400 MHz, CDCl3) δ 9.04 (bs, 1H, NH), 7.98 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 6.0 Hz, 1H), 7.52 
(dd, J = 6.0, 2.0 Hz, 1H), 7.19-7.17 (m, 2H), 6.49 (d, J = 8.4 Hz, 1H), 3.65 (d, J = 14.4, 1H), 
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3.47 (bs, 1H, OH), 3.36-3.41 (m, 1H), 3.32 (q, J = 9.2 Hz, 1H), 3.23 (d, J = 14.4, 1H), 2.99-2.91 
(m, 2H), 1.56 (s, 3H).  
(S)-N-(3-Chloro-4-cyanophenyl)-3-(6-fluoroindolin-1-yl)-2-hydroxy-2-
methylpropanamide (21d).  By Method B: Yield 68%; MS (ESI) m/z 372.1 [M – H] – ; 396.3 
[M + Na] +; 1H NMR (400 MHz, CDCl3) δ 9.08 (bs, 1H, NH), 7.98 (d, J = 1.6 Hz, 1H), 7.60 (d, J 
= 8.6 Hz, 1H), 7.54 (dd, J = 8.6, 1.6 Hz, 1H), 6.98 (t, J = 6.4 Hz, 1H), 6.40 (m, 1H), 6.38 (d, J 
=10.0 Hz, 1H), 3.65 (d, J = 14.4 Hz, 1H), 3.51 (bs, 1H, OH), 3.50-3.45 (m, 1H), 3.40 (q, J = 9.2 
Hz, 1H), 3.23 (d, J = 14.2 Hz, 1H), 3.00-2.87 (m, 2H), 1.56 (s, 3H). 
(S)-N-(3-Chloro-4-cyanophenyl)-3-(5,6-difluoroindolin-1-yl)-2-hydroxy-2-
methylpropanamide (21e).  By Method B: Yield 64%; MS (ESI) m/z 390.0 [M – H] –; 1H NMR 
(400 MHz, CDCl3) δ 9.05 (bs, 1H, NH), 7.98 (s, 1H), 7.62 (d, J = 8.2 Hz, 1H), 7.53 (d, J = 8.2 
Hz, 1H), 6.88 (t, J = 8.8 Hz, 1H), 6.43 (m, 1H), 3.95-3.88 (m, 2H), 3.64 (d, J = 14.4 Hz, 1H), 
3.46 (s, 1H, OH),  3.44 (m, 1H), 3.42-3.34 (m, 1H), 3.16 (d, J = 14.4 Hz, 1H), 1.55 (s, 3H).  
(S)-N-(3-Chloro-4-cyanophenyl)-3-(5-fluoro-6-phenylindolin-1-yl)-2-hydroxy-2-
methylpropanamide (21f).  To a solution of compound 19f (185 mg, 0.413 mmol) in 5 mL of 
glacial acetic acid which was cooled in an ice-water bath, was added dropwise sodium 
cyanoborohydride (1.0 M in THF, 0.62 mL, 1.24 mmol) under as argon atmosphere. After 
addition, the resulting reaction mixture was allowed to stir for overnight at room temperature 
under argon. The reaction was quenched by aqueous NH4Cl solution, and extracted with ethyl 
acetate. The organic layer was washed with brine twice, dried with MgSO4, filtered, and 
concentrated under vacuum. The product was purified by a silica gel column using ethyl acetate 
and hexane (1:2, v/v) as eluent to afford 0.17 g of the titled compound as yellowish foam.  Yield 
= 42%; 1H NMR (400 MHz, DMSO-d6) 10.29 (s, 1H, NH), 8.21 (d, J = 2.0 Hz, 1H, ArH), 
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7.92-7.84 (m, 2H, ArH), 7.45-7.34 (m, 5H, ArH), 6.95 (d, J = 10.4 Hz, 1H, ArH), 6.55 (d, J = 6.4 
Hz, 1H, ArH), 6.02 (s, 1H, OH), 4.50 (d, J = 14.4 Hz, 1H, CH), 4.19 (d, J = 14.4 Hz, 1H, CH), 
3.61 (q, J = 8.8 Hz, 1H, CH), 3.40 (d, J = 14.4 Hz, 1H, CH), 2.91 (t, J = 8.4 Hz, 2H, CH2), 1.42 
(s, 3H, CH3); MS (ESI, Positive) m/z 450.1394 [M + H] 
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Biological Experiments:  Plasmid constructs and transient transfection. GRE-LUC, 
CMV-renilla LUC, and CMV-hAR, used for the transient transfection assays were described 
earlier.28 Transient transactivation studies were performed in HEK-293 or COS cells using 
Lipofectamine as described before. Briefly, cells were plated in 24-well plates at 70,000 
cells/well in Dulbecco’s Medium Eagle plus 5% charcoal-stripped fetal bovine serum (csFBS) 
wiethout phenol red. Twenty four hours after plating, the cells were transfected with 0.25 g 
GRE-LUC, 10 ng CMV-LUC, and 25 ng CMV-hAR using Lipofectamine in OptiMEM medium. 
Cells were treated 24 h after transfection with a dose response of antagonists in combination with 
0.1 nM R1881 (i.e., antagonist mode) and luciferase assay was performed 48 h after transfection. 
Firefly luciferase values were normalized to renilla luciferase values.  Agonist mode experiments 
were run in some cases and were similar to antagonist mode except the dose response was the 
agonist in question without any antagonist nor co-treatment with R1881. 
Competitive ligand binding assay. A ligand binding assay with purified GST-tagged AR-
LBD and 1 nM 3H-mibolerone was performed as described previously.28 Purified AR 
protein was incubated with 1 nM  3H-mibolerone, a dose response of SARDs (1 pM to 100 
M) or DHT (used as control in all experiments) for 16 h at 4 °C. The protein complex was 
precipitated using hydroxyapatite (Bio-Rad, Hercules, CA), washed 4-6 times, and the bound 
radioactivity was eluted using 100% ethanol. The eluted tritium was counted using a scintillation 
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counter. The inhibitory constant (Ki) was obtained from modeling the data using SigmaPlot 
® software. The values are expressed as relative to DHT with DHT taken as 1 nM. 
Western blotting. Cells were plated at 1-1.5 million cells per well in 6-well plates or in 
60 mm plates in RPMI + 1%  csFBS containing medium and treated as described in the respective 
figures. Protein extracts were prepared 24 h after treatment, fractionated with SDS 
polyacrylamide gel electrophoresis (SDS-PAGE), and Western blot was performed using 
respective antibodies as described previously.28 Experiments with the proteasome inhibitor 
bortezomib were conducted in MR49F cells plated in growth medium and treated with 10 µM 
bortezomib alone or in combination with 10 µM of 19b or 19f. Cells were simultaneously treated 
with 50 µM cycloheximide. Cells were harvested 8 hours after treatment and Western blot for AR 
and GAPDH was performed. 
   
Proliferation assay. Cells were plated in characoal-stripped FBS-containing medium in 
96 well plates. Cells were treated with the indicated doses of the compound.  Three days after the 
initial treatment, cells were re-treated in fresh medium.  Six days after treatment cells were fixed 
and stained with sulforhodamine B dye and the number of viable cells was measured at O.D. 535 
nm.  
Metabolic stability in mouse liver microsomes. Test compound stock solutions were 
prepared at 10 mM in DMSO. They were diluted to a concentration of 50 M in 50% 
ACN/H2O resulting in a working stock solution of 100 X. Liver microsomes were utilized at a 
final concentration of 1.0 mg/mL of protein. Duplicate wells were used for each time point 
(0, 5, 10, 30, and 60 minutes). 
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Cofactors were added for phase II. Reactions were carried out at 37°C in a shaking water 
bath, and the final concentration of solvent was kept constant at 0.5%. At each time point, 100 
L of reaction was removed and added to a sample well containing 100 L of ice-cold, 100% 
ACN (plus internal standard), to stop the reaction. The final volume for each reaction was 200 
L, composed of: 66 L of 0.2 M KPO4 buffer, (pH 7.4); 50 L of NRS solution; and 10 L of 
microsomes (20 mg/ml stock).  The NRS is a solution of glucose-6-phosphate dehydrogenase, 
NADP+, MgCl2, and glucose-6-phosphate, prepared per manufacturer’s instructions.  Each 5.0 
mL stock of NRS solution contains 3.8 mL H2O, 1.0 mL solution “A”, and 0.2 mL solution 
“B”. Reactions from the positive control wells (verapamil, 0.5 M) were stopped with ice cold 
ACN containing internal standard. 
Fluorescence polarization.  Fluorescence polarization studies to determine the binding 
of the SARDs to AF-1 domain of the AR was conducted as published earlier.28  
 Xenograft studies.  All animal protocols were approved by the University of Tennessee 
Health Science Center Animal Care and Use Committee. Male NSG mice (6-8 weeks old) 
purchased from JAX labs (Bar Harbor, ME) were housed as five animals per cage and were 
allowed free access to water and commercial rodent chow (Harlan Teklad 22/5 rodent diet - 
8640). Cell line xenografts were performed as previously published.28 Enz-R LNCaP cells (i.e., 
MR49F cells, a kind gift from Dr. Martin Gleeve, University of British Columbia) (5 million) grown 
in growth medium were mixed with Matrigel (BD Biosciences, San Jose, CA) at 1:1 ratio and 
injected subcutaneously in NSG mice. Once tumor sizes reached 100-200 mm3, the animals 
were castrated and the tumors were allowed to regrow as CRPC. The animals were randomized 
once the tumors started to regrow and treated with vehicle (polyethylene glycol-300: DMSO 
85:15 ratio) or SARDs orally. Tumor volume was calculated using the formula 
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length*width*width*0.5236. At the end of the experiments, animals were sacrificed, tumors were 
weighed and collected for further processing.  
 Hershberger assay.  Male C57B/L6 mice or Sprague Dawley rats were treated as indicated 
in the figures.  Fourteen days after treatment, the animals were sacrificed and the weights of 
androgen-dependent tissues, prostate and seminal vesicles were recorded and represented as 
percent change from vehicle-treated animals.  As prostate is too small to precisely excise from 
mice, only seminal vesicles were obtained and reported. 
   
Ancillary Information. 
Supporting Information.  
The Supporting Information is available free of charge on the ACS Publications website.  
Additional information on compound characterization; additional biological experiments and 
figures (PDF) 
Molecular formula strings (CSV) 
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Table 1. Initial biological evaluation of SARDs (class I) 
 
 
ID 
Our Initial Set of Compounds 
(Leading to Class I a AR 
Degraders) 
Binding (Ki)/Transactivation (IC50) (M) SARD Activity (% degradation) 
Ki (DHT = 1 nM)
 b           IC
50
 c Full Length d,e Splice Variant d,e 
(LNCaP)@1 M (22RV1) @10 M 
 
1 
 
0.032 f, 27 > 10 ++ + 
 
8 
 
>10 f, 27 0.392 ++ - 
3  
 
0.078 g, 28 0.048 g,28 +++ +++ 
 
a Class I is defined to be selective androgen receptor degraders in which the linker is a straight chain (e.g., 
butanamides or amino-propanamides).  b AR binding was determined by competitive binding of 1 nM [3H]-
mibolerone to recombinant ligand binding domain (LBD) of wildtype AR. DHT (1 nM) is used in each 
experiment as a standard agent.  c Inhibition of transactivation was determined by transfecting HEK-293 cells 
with full length wildtype AR, GRE-LUC, and CMV-renilla luciferase for transfection control. And then 24 h 
later, treatment with 0.1 nM R1881 agonist and a dose response of antagonist (1 pM to 10 M in log units) for 24 
h. Twenty four hours after treatment, cells were harvested and luciferase assay was performed using Dual 
Luciferase assay kit.  d SARD activity was determined by treating LNCaP or 22RV1 cells, respectively, for 
determining FL AR or SV AR protein levels.  Cells were maintained in charcoal-stripped serum-containing 
medium for 48 h and treated with the indicated doses of antagonist for 24 h in the presence of 0.1 nM R1881 
(agonist). Cells were harvested and Western blot for AR was performed using AR-N20 antibody that is directed 
towards the N-terminal domain (NTD) of AR. The AR and AR SV bands were quantified and normalized to actin 
Western blots.  e AR protein levels are reported qualitatively using the following abbreviations: -, no degradation 
(inactive); +, < 30% degradation (weak SARD activity); ++, 31 ~ 60% degradation (moderate SARD activity); 
+++, 61 ~ 90% degradation (strong SARD activity); ++++: > 90% degradation (complete SARD activity).  f 
Binding data was determined as reported.27  g We previously reported this binding and transactivation data in the 
same assays as reported here.28   
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Table 2. Summary of structures of indolyl and indolinyl propanamides (Class II and III) 
 
            ID       Structure               ID       Structure               ID       Structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   II 
728  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   II 
18m  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   III 
 
20a   
 
7r28 
 
18n  
  
20b  
  
18a   
  
18o   
  
20e   
  
18b   
  
18p 
    
20f   
  
18c   
  
18q 
   
 
20g   
  
18e   
 
19a 
 
21a  
 
18f   
  
19b   
  
21b   
  
18g   
  
19c   
  
21c   
  
18i   
  
19d   
  
21d   
  
18j   
  
19e   
  
21e 
 
18k  
  
19f   
  
21f   
  
18l   
 
19g   
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Table 3. In vitro pharmacological activity of indolyl derivatives II 
 
                         ID  
                    Class II a 
Binding (Ki) / Transactivation (IC50) (M)       SARD Activity (% degradation) 
Ki  (DHT = 1 nM) b          IC
50 
b      Full Length b    Splice Variant b 
  (LNCaP)@1 M (22RV1)@10 M 
              
    II 
(3’-CF3) 
7 (5-F) 0.267 0.085 +++ +++ 
7r (R-7) >10.0 0.598 +++ +++ 
18a (unsub.) 2.080 0.064 + ++ 
18b (4-F) 0.419 0.127 ++ ++ 
18c (6-F) 0.212 0.085 - +++ 
18e (5-NO2) 0.433 0.088 ++ +++ 
18f (6-NO2) 0.047 0.058 - +++ 
18g (3-Me, 5-F) 0.547 0.157 ++ +++ 
18i (5-F, 6-Ph) 0.124 0.215 ++ + 
18j (5-Br) 0.316 0.918 - - 
18k (5-I) 0.294 0.985 - + 
18l (3-CO2H) >10.0 >10.0 - - 
18m (3-CO2Et)  0.995 0.972 - - 
18n (4-pyridino, 5-CN) >10.0 0.686 + + 
18o (4-Ph) 0.084 >10.0 - - 
18p (4-F, 5-Ph)  0.086 1.015 - - 
18q (4-F, 6-(4-F-Ph)) 0.062 0.898 - - 
               
     II 
  (3’-Cl) 
19a (3-F) 0.332 0.045 +++ +++ 
19b (4-F) 0.315 0.142 +++ ++ 
19c (5-F) 0.253 0.094 +++ + 
19d (6-F) 0.156 0.099 +++ - 
19e (7-F) 0.720 0.234 ++ + 
19f (5-F, 6-Ph) 0.133 0.203 ++ ++ 
19g (3-Ph, 5-F) 0.135 1.032 - - 
       2 [Enobosarm] c   0.0038     0.0038 c Agonist d Agonist d 
       4 [R-Bicalutamide] 0.509 0.248 - - 
       5 [Enzalutamide] 3.641 0.216 - - 
       6 [Apalutamide] e 1.452   0.016 e + - 
 
a Class II is defined to be selective androgen receptor degraders in which the B-ring is substituted or 
unsubstituted N-linked indole(i.e., indol-1-yl). b AR binding, transactivation, and degradation assays were 
performed and values reported as described in Table 1. c In vitro transcriptional activation was run in agonist 
mode and the EC50 value was previously reported.
36   d Enobosarm is a full agonist that increases AR 
expression at the protein level. e In vitro transcriptional activation was run in antagonist mode and the IC50 
value was previously reported.51 
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Table 4. In vitro pharmacological activity of indolinyl derivatives III 
 
              ID  
         Class III a 
Binding (Ki) / Transactivation (IC50) (M)       SARD Activity (% degradation) 
   Ki (DHT=1nM) b           IC
50
 b        Full Length    Splice Variant  
 (LNCaP)@1 M b  (22RV1)@10 M b  
     III 
(3’-CF3) 
20a (unsub.) >1.0 0.142 +++ ++ 
20b (4-F) 0.170 0.059 +++ + 
20e (6-F) 0.273 0.039 +++ ++ 
20f (5,6-diF) 0.115 0.101c ++ ++ 
20g (5-Cl, 6-F) 0.068 AG c - - 
    III 
 (3’-Cl) 
21a (4-F) 0.382 0.126 ++ +++ 
21b (5-F) 0.326 0.130 ++ + 
21c (5-Br) 0.204 0.835 ++ - 
21d (6-F) 0.490 0.037 ++++ + 
21e (5,6-diF) 0.252 0.032 +++ ++ 
21f (5-F, 6-Ph) 0.071 0.244 ++++ +++ 
5 3.641 0.216 - - 
 
a Class III is defined to be selective androgen receptor degraders in which the B-ring is substituted or 
unsubstituted N-linked indoline (i.e., indolin-1-yl).  b AR binding, transactivation, and degradation assays 
were performed and values reported as described in Table 1. c AG, showed agonist activity. 
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Table 5. In vitro metabolic stability of II and III in mouse liver microsomes (MLM)  
 
                      
                            ID 
               MLM a                 
                           ID 
                 MLM a 
T1/2  (min)       CLint 
(mL/min/mg) 
T1/2  (min)       CLint 
(mL/min/mg) 
II (3’-CF3) 
 
 
 
18 (5-F) 12.35 56.14 II (3’-Cl) 19a (3-F)   9.29        74.6 
18a (unsub.) 13.66 50.75 19b (4-F) 11.77        58.8 
18b (4-F) 36.32 19.08 19f (5-F, 6-Ph)   9.13 75.91 
18c (6-F) 22.39 30.96 III (3’-CF3) 
III (3’-Cl) 
20b (4-F) 25.06 27.67 
18e (5-NO2) 19.27 35.97 21a (4-F) 15.00 46.22 
18f (6-NO2) 13.48 51.43 21b (5-F)   9.16 23.77 
18g (3-Me, 5F) 21.77 31.84  
 
21c (5-Br) 17.35 39.36 
18i (5F, 6Ph) 15.43 44.94 21f (5-F, 6-Ph) 21.37 32.44 
18j (5-Br) 17.02 40.73 21c (5-Br) 17.35 39.36 
18k (5-I) 20.37 34.02    
18l (3-CO2H) 29.79 23.28 Antagonist 5    10.04
b 86.3c 
18m (3-CO2Et) 25.78 26.89 
Agonist 2      360.0  1.4 
 
a Compounds are incubated together with MLM with co-factors for phase I and II provided, as described 
in the Experimental section.  b T1/2 (h) after oral administration in humans as previously reported.51 c CL 
(mL/h/kg) after oral administration in humans as previously reported.51 
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Figure 1. Known small molecule AR ligands: antagonists, agonist and degrader.   
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Figure 2. Design of diaryl indolyl and indolinyl propanamides (II and III) by structural 
modification of AR antagonists, e.g., 127 and agonists, e.g., 236 to produce several classes of AR 
degraders.  
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Figure 3: Degradation of FL and SV AR by selected SARDs. LNCaP (A) or 22RV1 (B) cells 
were plated in full-serum containing medium. Medium was changed to 1% charcoal-stripped 
serum containing medium and maintained in this medium for 2 days. Medium was changed 
again and the cells were treated with 0.1 nM R1881 (agonist) and either vehicle or a titration of 
SARD as indicated in the figure. Twenty-four hours after treatment, cells were harvested, protein 
extracted, and the proteins were blotted with AR-N20 antibody. Blots were stripped and re-
probed with an actin antibody. The ratio of AR to actin for each lane is given under each blot.  
AR- full length androgen receptor; AR-SV- androgen receptor splice variant. 
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Figure 4: SARDs antagonize transactivation and degrade Enz-R conferring escape mutant AR.  A. 
AR with phenylalanine 876 mutated to leucine (F876L), GRE-LUC, and CMV-renilla LUC were 
transfected in COS cells. Cells were treated 24 h after transfection with 0.1 nM R1881 (agonist) and a 
dose response of antagonists. Luciferase assay was performed 48 h after transfection. The effect of 
compound 5 was conducted in both antagonistic mode (in the presence of 0.1 nM R1881) and in agonistic 
mode (in the absence of 0.1 nM R1881). The agonist activity has been labeled in the figure as 5 (Agonist). 
B. Enzalutamide-resistant LNCaP cells (MR49F) were maintained in charcoal-stripped, serum containing 
medium for 2 d and treated with 0.1 nM R1881 (agonist) and a titration of the SARD or enzalutamide as 
indicated in the figure. 
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Figure 5: Enzalutamide-Resistant LNCaP (MR49F) Cellular Anti-Proliferation: A. 
Enzalutamide-resistant LNCaP (MR49F) cells were plated in 1% charcoal-stripped, serum-
containing medium and treated with 0.1 nM R1881 and titration of antagonist as indicated in the 
figure.  Cells were re-treated 3 d after the first treatment and the number of viable cells measured 
by Cell-Titer Glo assay (Promega, Madison, WI). N = 3. * = p < 0.05. B.   PC-3 cells were 
incubated with the indicated doses of the compounds in csFBS-containing medium. Medium was 
changed and the cells were re-treated after 3 days. Sulforhodamine B assay was performed after 
6 days of treatment. 
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Figure 6:  Proteasome inhibitor reverses the degradation of 19f and 19b in MR49F cells: 
LNCaP Enz-R cells (MR49F) were maintained in RPMI+10% FBS medium. Cells were treated 
in this medium for 8 hours. Cells were harvested, protein extracted, and Western blot for AR and 
GAPDH was performed. Quantification is provided at the bottom on the blots. 
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Figure 7: SARDs inhibit androgen-dependent organs in mice and rats and inhibit growth of 
enzalutamide-resistant prostate cancer. A. Mice (left) or rats (right) were treated with vehicle 
or indicated SARDs (40 mg/kg/day left panel) orally (n=5/group). Animals were sacrificed 14 d 
after treatment and weights of prostate and seminal vesicles were measured and normalized to 
body weight. B. Enzalutamide resistant LNCaP cells (5 million/mouse) were implanted 
subcutaneously in male NOD SCID Gamma (NSG) mice (n = 7-9 per group). Animals were 
castrated when the tumors reached 100-200 mm3 and allowed to regrow as castration-resistant 
tumors. Animals were treated orally with vehicle (DMSO:PEG-300 15:85) or 100 mg/kg/day of 
SARD or 30 mg/kg/day of enzalutamide. Tumor volume was measured twice weekly and 
represented as percent change. Values are expressed as average ± S.E. *= p < 0.05.    
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Scheme 1. Generic synthesis of class II (compounds 7, 7r, 18a ~ 19g) and III (compounds 20a 
~ 21f), Reagent and conditions: (a) SOCl2, THF, 0 °C; (b) 2-butanone, K2CO3, reflux; (c) NaH, 
THF, 0 °C ~ room temperature; (d) LDA, THF, -78 °C ~ room temperature.  * 7r (R-isomer of 7) 
was prepared from L-proline by same procedure as for 7. 
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